# EDGAR Filing Document

**Accession Number:** 0001776738
**File Stem:** 0001776738-25-000038
**Filing Date:** 2025-8
**Character Count:** 181563
**Document Hash:** 2660efbdcdde532d22134b6213577437
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001776738-25-000038.hdr.sgml**: 20250807

**ACCESSION NUMBER**: 0001776738-25-000038

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 90

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250807

**DATE AS OF CHANGE**: 20250807

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cannabist Co Holdings Inc.
- **CENTRAL INDEX KEY:** 0001776738
- **STANDARD INDUSTRIAL CLASSIFICATION:** AGRICULTURE PRODUCTION - CROPS [0100]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 981488978
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-56294
- **FILM NUMBER:** 251192993

**BUSINESS ADDRESS:**
- **STREET 1:** 321 BILLERICA ROAD
- **CITY:** CHELMSFORD
- **STATE:** MA
- **ZIP:** 01824
- **BUSINESS PHONE:** 2125543424

**MAIL ADDRESS:**
- **STREET 1:** 321 BILLERICA ROAD
- **CITY:** CHELMSFORD
- **STATE:** MA
- **ZIP:** 01824

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Columbia Care Inc.
- **DATE OF NAME CHANGE:** 20190514

?xml version='1.0' encoding='ASCII'? cbstf-20250630

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

_________________________________________________________

**FORM 10-Q**

_________________________________________________________

**(Mark One)**

⌧ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended June 30, 2025**

**OR**

□ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from __to __**

**Commission File Number: 000-56294**

_________________________________________________________

![Image 2.jpg](cbstf-20250630_g1.jpg)

**THE CANNABIST COMPANY HOLDINGS INC.**

**(Exact Name of Registrant as Specified in its Charter)**

_________________________________________________________

---

| | |
|:---|:---|
| **British Columbia** | **98-1488978** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(I.R.S. Employer**<br>**Identification No.)** |
| **321 Billerica Rd., Suite 204** <br>**Chelmsford, Massachusetts** | **01824** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (978) 910-1486**

_________________________________________________________

Securities registered pursuant to Section 12(b) of the Act: None

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange on which registered** |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No □

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No □

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | □ | Accelerated filer | ⌧ |
| Non-accelerated filer | □ | Smaller reporting company | □ |
| Emerging growth company | ⌧ | | |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes □ No ⌧

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes □ No □

As of August 4, 2025, there were 491,745,341 shares of common stock, no par value per share (the "Common Shares"), outstanding.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

**Table of Contents**

---

| | | |
|:---|:---|:---|
| | | &nbsp;&nbsp;**Page** |
| <u>[FORWARD-LOOKING STATEMENTS](#if4efeb26950b44de969aebf0b8cd78b7_10)</u> | <u>[FORWARD-LOOKING STATEMENTS](#if4efeb26950b44de969aebf0b8cd78b7_10)</u> | [2](#if4efeb26950b44de969aebf0b8cd78b7_10) |
| **[PART I.](#if4efeb26950b44de969aebf0b8cd78b7_13)** | [FINANCIAL INFORMATION](#if4efeb26950b44de969aebf0b8cd78b7_13) |  |
| [Item 1.](#if4efeb26950b44de969aebf0b8cd78b7_16) | [Financial Statements (Unaudited)](#if4efeb26950b44de969aebf0b8cd78b7_16) |  |
|  | <u>[Condensed Consolidated Interim Balance Sheets](#if4efeb26950b44de969aebf0b8cd78b7_19)</u> | [4](#if4efeb26950b44de969aebf0b8cd78b7_19) |
|  | <u>[Condensed Consolidated Interim Statements of Operations and Comprehensive Loss](#if4efeb26950b44de969aebf0b8cd78b7_25)</u> | [5](#if4efeb26950b44de969aebf0b8cd78b7_25) |
|  | <u>[Condensed Consolidated Interim Statements of Changes in Equity](#if4efeb26950b44de969aebf0b8cd78b7_28)</u> | [6](#if4efeb26950b44de969aebf0b8cd78b7_28) |
|  | <u>[Condensed Consolidated Interim Statements of Cash Flows](#if4efeb26950b44de969aebf0b8cd78b7_31)</u> | [7](#if4efeb26950b44de969aebf0b8cd78b7_31) |
|  | <u>[Notes to](#if4efeb26950b44de969aebf0b8cd78b7_34)[the](#if4efeb26950b44de969aebf0b8cd78b7_34)[Condensed Consolidated Interim Financial Statements](#if4efeb26950b44de969aebf0b8cd78b7_34)</u> | [9](#if4efeb26950b44de969aebf0b8cd78b7_34) |
| [Item 2.](#if4efeb26950b44de969aebf0b8cd78b7_97) | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#if4efeb26950b44de969aebf0b8cd78b7_97)</u> | [25](#if4efeb26950b44de969aebf0b8cd78b7_97) |
| [Item 3.](#if4efeb26950b44de969aebf0b8cd78b7_115) | <u>[Quantitative and Qualitative Disclosures About Market Risk](#if4efeb26950b44de969aebf0b8cd78b7_115)</u> | [36](#if4efeb26950b44de969aebf0b8cd78b7_115) |
| [Item 4.](#if4efeb26950b44de969aebf0b8cd78b7_118) | <u>[Controls and Procedures](#if4efeb26950b44de969aebf0b8cd78b7_118)</u> | [36](#if4efeb26950b44de969aebf0b8cd78b7_118) |
| **[PART II.](#if4efeb26950b44de969aebf0b8cd78b7_121)** | <u>[OTHER INFORMATION](#if4efeb26950b44de969aebf0b8cd78b7_121)</u> | [37](#if4efeb26950b44de969aebf0b8cd78b7_121) |
| [Item 1.](#if4efeb26950b44de969aebf0b8cd78b7_124) | <u>[Legal Proceedings](#if4efeb26950b44de969aebf0b8cd78b7_124)</u> | [37](#if4efeb26950b44de969aebf0b8cd78b7_124) |
| [Item 1A.](#if4efeb26950b44de969aebf0b8cd78b7_127) | <u>[Risk Factors](#if4efeb26950b44de969aebf0b8cd78b7_127)</u> | [37](#if4efeb26950b44de969aebf0b8cd78b7_127) |
| [Item 2.](#if4efeb26950b44de969aebf0b8cd78b7_130) | <u>[Unregistered Sales of Equity Securities and Use of Proceeds](#if4efeb26950b44de969aebf0b8cd78b7_130)</u> | [37](#if4efeb26950b44de969aebf0b8cd78b7_130) |
| [Item 3.](#if4efeb26950b44de969aebf0b8cd78b7_133) | <u>[Defaults Upon Senior Securities](#if4efeb26950b44de969aebf0b8cd78b7_133)</u> | [37](#if4efeb26950b44de969aebf0b8cd78b7_133) |
| [Item 4.](#if4efeb26950b44de969aebf0b8cd78b7_136) | <u>[Mine Safety Disclosures](#if4efeb26950b44de969aebf0b8cd78b7_136)</u> | [37](#if4efeb26950b44de969aebf0b8cd78b7_136) |
| [Item 5.](#if4efeb26950b44de969aebf0b8cd78b7_139) | <u>[Other Information](#if4efeb26950b44de969aebf0b8cd78b7_139)</u> | [37](#if4efeb26950b44de969aebf0b8cd78b7_139) |
| [Item 6.](#if4efeb26950b44de969aebf0b8cd78b7_142) | <u>[Exhibits](#if4efeb26950b44de969aebf0b8cd78b7_142)</u> | [37](#if4efeb26950b44de969aebf0b8cd78b7_142) |
| <u>[Signatures](#if4efeb26950b44de969aebf0b8cd78b7_145)</u> |  | [40](#if4efeb26950b44de969aebf0b8cd78b7_145) |

---

i

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

**FORWARD-LOOKING STATEMENTS**

This Quarterly Report on Form 10-Q contains "forward-looking statements" regarding The Cannabist Company Holdings Inc. and its subsidiaries (collectively referred to as "The Cannabist Company," "we," "us," "our," or the "Company"). We make forward-looking statements related to future expectations, estimates, and projections that are uncertain and often contain words such as, but not limited to, "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" or other similar words or phrases. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and assumptions that are difficult to predict. Particular risks and uncertainties that could cause our actual results to be materially different from those expressed in our forward-looking statements include those listed below:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of the Company's corporate restructuring activities, including, without limitation, the Company's debt restructuring as contemplated by the Support Agreement (as defined below);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the fact that marijuana remains illegal under federal law;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the application of anti-money laundering laws and regulations to the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• legal, regulatory, or political change to the cannabis industry;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• access to public and private capital;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• unfavorable publicity or consumer perception of the cannabis industry;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• expansion to the adult-use markets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of laws, regulations, and guidelines;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of Section 280E of the U.S. Internal Revenue Code of 1986, as amended (the "**Internal Revenue Code**");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of state laws pertaining to the cannabis industry;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Company's reliance on key inputs, suppliers and skilled labor;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the difficulty of forecasting the Company's sales;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• constraints on marketing products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• potential cyber-attacks and security breaches;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• net operating loss and other tax attribute limitations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of changes in tax laws;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the volatility of the market price of the Company's common shares;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reliance on management;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• litigation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• future results and financial projections; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of global financial conditions.

The list of factors above is illustrative and by no means exhaustive. Additional information regarding these risks and other risks and uncertainties we face is contained in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2024, as well as subsequent filings. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated, or intended.

We urge readers to consider these risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

**THE CANNABIST COMPANY HOLDINGS INC.**

CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS

(Unaudited)

(Expressed in thousands of U.S. dollars, except share data)

---

| | | |
|:---|:---|:---|
| | **June 30, 2025** | **December 31, 2024** |
| **Assets** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;Cash | $15456 | $33607 |
| &nbsp;&nbsp;Accounts receivable, net of credit loss allowance of $7,113 and $6,754, respectively | 19207 | 21688 |
| &nbsp;&nbsp;Inventory | 70905 | 94516 |
| &nbsp;&nbsp;Prepaid expenses and other current assets | 13310 | 11794 |
| &nbsp;&nbsp;Notes receivable | 571 | 15614 |
| &nbsp;&nbsp;Assets held for sale | 48709 | 17778 |
| &nbsp;&nbsp;Total current assets | 168158 | 194997 |
| Property and equipment, net | 212442 | 228396 |
| Right of use assets - operating leases, net | 98208 | 124739 |
| Right of use assets - finance leases, net | 22481 | 25515 |
| Intangible assets, net | 41487 | 51249 |
| Investments | 3860 | 11880 |
| Deferred income tax assets | 331 | 32025 |
| Notes receivable | 3977 | 11958 |
| Other non-current assets | 12894 | 15414 |
| Total assets | $563838 | $696173 |
| **Liabilities and Equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;Accounts payable | $28835 | $41125 |
| &nbsp;&nbsp;Accrued expenses and other current liabilities | 18551 | 32839 |
| &nbsp;&nbsp;Income tax payable | 87606 | 87333 |
| &nbsp;&nbsp;Current portion of lease liabilities - operating leases | 6748 | 7386 |
| &nbsp;&nbsp;Current portion of lease liabilities - finance leases | 4027 | 4910 |
| &nbsp;&nbsp;Current portion of long-term debt, net | 754 | 52461 |
| &nbsp;&nbsp;Liabilities held for sale | 32486 | 2656 |
| &nbsp;&nbsp;Total current liabilities | 179007 | 228710 |
| Long-term debt, net | 297704 | 249512 |
| Long-term lease liabilities - operating leases | 99287 | 126215 |
| Long-term lease liabilities - finance leases | 35978 | 37937 |
| Derivative liabilities | 980 | 621 |
| Other long-term liabilities | 89728 | 83237 |
| Total liabilities | 702684 | 726232 |
| Commitments and contingencies |  |  |
| Stockholders' Equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common Stock, no par value, unlimited shares authorized as of June 30, 2025 and December 31, 2024, respectively, 491,745,341 and 465,638,304 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Preferred Stock, no par value, unlimited shares authorized as of June 30, 2025 and December 31, 2024, respectively, none issued and outstanding as of June 30, 2025 and December 31, 2024 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proportionate voting shares, no par value, unlimited shares authorized as of June 30, 2025 and December 31, 2024, respectively, 7,387,328 and 7,387,328 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively |  |  |
| &nbsp;&nbsp;Additional paid-in-capital | 1157612 | 1156807 |
| &nbsp;&nbsp;Accumulated deficit | (1295586) | (1185501) |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity attributable to The Cannabist Company Holdings Inc. | (137974) | (28694) |
| &nbsp;&nbsp;Non-controlling interest | (872) | (1365) |
| &nbsp;&nbsp;Total equity | (138846) | (30059) |
| &nbsp;&nbsp;Total liabilities and equity | $563838 | $696173 |

---

The accompanying notes are an integral part of these unaudited Condensed Consolidated Interim Financial Statements.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

**THE CANNABIST COMPANY HOLDINGS INC.**

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(Expressed in thousands of U.S. dollars, except for number of shares and per share amounts)

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended** | **Three months ended** | **Six months ended** | **Six months ended** |
| | **June 30, 2025** | **June 30, 2024** | **June 30, 2025** | **June 30, 2024** |
| Revenues, net of discounts | $86350 | $125190 | $173790 | $247801 |
| Cost of sales related to inventory production | (69197) | (77138) | (127352) | (157212) |
| Gross margin | 17153 | 48052 | 46438 | 90589 |
| &nbsp;&nbsp;&nbsp;Fixed asset impairment |  |  | (193) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative expenses | (32990) | (40046) | (70241) | (93319) |
| Profit (loss) from operations | (15837) | 8006 | (23996) | (2730) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other expense: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense on leases | (712) | (895) | (1442) | (1835) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (14685) | (9716) | (23839) | (18750) |
| &nbsp;&nbsp;&nbsp;Other income (expense), net | (2931) | (1396) | (16300) | (6386) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other expense | (18328) | (12007) | (41581) | (26971) |
| Loss before provision for income taxes | (34165) | (4001) | (65577) | (29701) |
| Income tax expense | (43221) | (9642) | (44015) | (18510) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss and comprehensive loss | (77386) | (13643) | (109592) | (48211) |
| &nbsp;&nbsp;Net profit attributable to non-controlling interests | 495 | 698 | 493 | $1203 |
| Net loss attributable to shareholders | $(77881) | $(14341) | $(110085) | $(49414) |
| Weighted-average number of shares used in earnings per share - basic and diluted | 484713110 | 460653957 | 478894930 | 453143911 |
| Loss attributable to shares (basic and diluted) | $(0.16) | $(0.03) | $(0.23) | $(0.11) |

---

The accompanying notes are an integral part of these unaudited Condensed Consolidated Interim Financial Statements.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

**THE CANNABIST COMPANY HOLDINGS INC.**

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY

(Unaudited)

(Expressed in thousands of U.S. dollars, except for number of shares)

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common<br>Shares** | **Proportionate<br>Voting Shares** | **Additional<br>Paid-in Capital** | **Accumulated<br>Deficit** | **Total The Cannabist Company Holdings Inc.<br>Shareholders' Equity** | **Non-Controlling<br>Interest** | **Total<br>Equity** |
| **Balance as of December 31, 2023** | **420265306** | **9807881** | $**1146154** | $**(1079282)** | $**66872** | $**(1520)** | $**65352** |
| Equity-based compensation (1) |  |  | 3182 |  | 3182 |  | 3182 |
| Conversion of convertible notes | 25845259 |  | 10000 |  | 10000 |  | 10000 |
| Conversion between classes of shares | 2106055 | (2106055) |  |  |  |  |  |
| Deconsolidation of subsidiary |  |  |  | (1058) | (1058) |  | (1058) |
| Net loss |  |  |  | (35073) | (35073) | 505 | (34568) |
| **Balance as of March 31, 2024** | **448216620** | **7701826** | $**1159336** | $**(1115413)** | $**43923** | $**(1015)** | $**42908** |
| Equity-based compensation (1) | 8225383 |  | (9399) |  | (9399) |  | (9399) |
| Conversion of convertible notes | 655736 |  | 200 |  | 200 |  | 200 |
| Legal settlement | 4845359 |  | 2620 |  | 2620 |  | 2620 |
| Deconsolidation of subsidiary |  |  |  | 1031 | 1031 |  | 1031 |
| Distributions |  |  |  | (333) | (333) |  | (333) |
| Net loss |  |  |  | (14341) | (14341) | 698 | (13643) |
| **Balance as of June 30, 2024** | **461943098** | **7701826** | $**1152757** | $**(1129056)** | $**23701** | $**(317)** | $**23384** |
| (1) The amount shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amount shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amount shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amount shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amount shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amount shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amount shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amount shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. |

---

**THE CANNABIST COMPANY HOLDINGS INC.**

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY - CONTINUED

(Unaudited)

(Expressed in thousands of U.S. dollars, except for number of shares)

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common<br>Shares** | **Proportionate<br>Voting Shares** | **Additional<br>Paid-in Capital** | | **Accumulated<br>Deficit** | | **Total The Cannabist Company Holdings Inc.<br>Shareholders' Equity** | | **Non-Controlling<br>Interest** | **Total<br>Equity** |
| **Balance as of December 31, 2024** | **465638304** | **7387328** | $**1156807** |  | $**(1185501)** |  | $**(28694)** |  | $**(1365)** | $**(30059)** |
| Equity-based compensation (1) | (93662) |  | 292 |  |  |  | 292 |  |  | 292 |
| Net loss |  |  |  |  | (32204) |  | (32204) |  | (2) | (32206) |
| **Balance as of March 31, 2025** | **465544642** | **7387328** | $**1157099** | $**—** | $**(1217705)** | $**—** | $**(60606)** | $**—** | $**(1367)** | $**(61973)** |
| Equity-based compensation (1) | 6872394 |  | 525 |  |  |  | 525 |  |  | 525 |
| Conversion of convertible note | 19328305 |  |  |  |  |  |  |  |  |  |
| Distributions |  |  | (12) |  |  |  | (12) |  |  | (12) |
| Net loss |  |  |  |  | (77881) |  | (77881) |  | 495 | (77386) |
| **Balance as of June 30, 2025** | **491745341** | **7387328** | $**1157612** | $**—** | $**(1295586)** | $**—** | $**(137974)** | $**—** | $**(872)** | $**(138846)** |
| (1) The amounts shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amounts shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amounts shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amounts shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amounts shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amounts shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amounts shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amounts shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amounts shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amounts shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amounts shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. |

---

The accompanying notes are an integral part of these unaudited Condensed Consolidated Interim Financial Statements.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

**THE CANNABIST COMPANY HOLDINGS INC.**

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

(Unaudited)

(expressed in thousands of U.S. dollars)

---

| | | |
|:---|:---|:---|
| | **Six months ended** | **Six months ended** |
| | **June 30, 2025** | **June 30, 2024** |
| **Cash flows from operating activities:** | | |
| &nbsp;&nbsp;Net loss | $(109592) | $(48211) |
| &nbsp;&nbsp;Adjustments to reconcile net loss to net cash (used in) operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 16851 | 27547 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation | 935 | (4962) |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt amortization expense | 10678 | 4307 |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for credit losses | 2238 | 964 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on deconsolidation of subsidiaries | 10494 | 624 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on early extinguishment of note | 3227 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for obsolete inventory and other assets | 10572 | 5642 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of derivative liabilities | 359 | 2329 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in investment fair value | 6520 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | 31694 | (1080) |
| &nbsp;&nbsp;&nbsp;&nbsp;Legal settlement |  | (1108) |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment on fixed assets | 193 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 106 | (343) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Changes in operating assets and liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (840) | (4868) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | 4656 | (10140) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | (2665) | (3214) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notes receivable | 19350 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets | 4082 | 728 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (9108) | 4138 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | (12616) | 12 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable | 273 | 17367 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other long-term liabilities | 1521 | 609 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities | (11072) | (9659) |
| **Cash flows from investing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of property and equipment | (3856) | (2629) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sale of license | 4000 | 329 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net proceeds from sale of businesses | 5687 | 2999 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash received on deposits, net | 108 | 157 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by investing activities | 5939 | 856 |
| **Cash flows from financing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of debt |  | 15600 |
| &nbsp;&nbsp;&nbsp;&nbsp;Payment of debt issuance costs | (12155) | (802) |
| &nbsp;&nbsp;&nbsp;&nbsp;Payment of lease liabilities | (1466) | (3582) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayment of sellers note |  | (750) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayment of debt | (100) | (13228) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayment of mortgage notes | (353) | (279) |
| &nbsp;&nbsp;&nbsp;&nbsp;Distributions | (12) | (333) |
| &nbsp;&nbsp;&nbsp;&nbsp;Taxes paid on equity based compensation | (120) | (1255) |
| &nbsp;&nbsp;Net cash used in financing activities | (14206) | (4629) |
| &nbsp;&nbsp;**Net decrease in cash** | (19339) | (13432) |
| &nbsp;&nbsp;Cash and restricted cash at beginning of the period | 37930 | 39337 |
| &nbsp;&nbsp;Cash and restricted cash at end of period | $18591 | $25905 |
| **Reconciliation of cash and restricted cash:** |  |  |
| Cash | $15456 | $22332 |
| Restricted cash | 3135 | 3573 |
| Cash and restricted cash, end of period | $18591 | $25905 |
| The accompanying notes are an integral part of these unaudited Condensed Consolidated Interim Financial Statements. | The accompanying notes are an integral part of these unaudited Condensed Consolidated Interim Financial Statements. | The accompanying notes are an integral part of these unaudited Condensed Consolidated Interim Financial Statements. |

---

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

**THE CANNABIST COMPANY HOLDINGS INC.**

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

(Unaudited)

(expressed in thousands of U.S. dollars)

---

| | | |
|:---|:---|:---|
| | **Six months ended** | **Six months ended** |
| | **June 30, 2025** | **June 30, 2024** |
| **Supplemental disclosure of cash flow information:** | | |
| Cash paid for amounts included in the measurement of lease liabilities: |  |  |
| &nbsp;&nbsp;Operating cash flows from operating leases | $9855 | $13565 |
| &nbsp;&nbsp;Operating cash flows from finance leases | $1438 | $1835 |
| &nbsp;&nbsp;Financing cash flows from finance leases | $2799 | $3582 |
| Cash paid for interest on other obligations | $26104 | $20575 |
| Cash paid for income taxes | $5766 | $1507 |
| Lease liabilities arising from the recognition of finance right-of-use assets | $— | $3639 |
| Lease liabilities arising from the recognition of operating right-of-use assets | $— | $7436 |
| **Supplemental disclosure of non-cash investing and financing activities:** |  |  |
| Non-cash fixed asset additions within accounts payable and accrued expenses | $— | $386 |
| Discount on issuance of convertible debt | $— | $(5150) |
| Reduction in debt from debt to equity conversion | $— | $(10200) |
| Increase in equity from debt to equity conversion | $— | $10200 |
| Equity issued for legal settlement | $— | $2620 |
| Exchange of notes and convertible notes for new notes and convertible notes | $269950 | $— |
| Assets held for sale | $30931 | $(1652) |
| Liabilities held for sale | $29830 | $1274 |

---

The accompanying notes are an integral part of these unaudited Condensed Consolidated Interim Financial Statements.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

**THE CANNABIST COMPANY HOLDINGS INC.**<br>NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS <br>FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025, and 2024<br>(Expressed in thousands of U.S. dollars, except for share and per share amounts)<br>(Unaudited)<br>

**1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OPERATIONS OF THE COMPANY**

The Cannabist Company Holdings Inc. ("the Company", "the Parent", or "The Cannabist Company"), formerly known as Columbia Care Inc., was incorporated under the laws of the Province of Ontario on August 13, 2018. The Company's principal mission is to improve lives by providing cannabis-based products to qualified patients and consumers. The Company's head office and principal address is 321 Billerica Rd., Suite 204, Chelmsford, Massachusetts 01824. The Company's registered and records office address is 666 Burrard St #1700, Vancouver, British Columbia V6C 2X8.

On April 26, 2019, the Company completed a reverse takeover ("RTO") transaction and private placement. Following the RTO, the Company's common shares were listed on Cboe Canada (formerly known as the NEO Exchange), trading under the symbol "CCHW". Effective September 19, 2023, the Company changed its name from "Columbia Care Inc." to "The Cannabist Company Holdings Inc." (the "Name Change"). In connection with the Name Change, on September 21, 2023, the Company's common shares and warrants began trading under the ticker symbols "CBST" and "CBST.WT", respectively, on Cboe Canada. On September 26, 2023, the Company's common shares began trading on the OTCQX Best Market under the ticker symbol "CBSTF," and transitioned to the OTCQB in April 2025.

**2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

***Basis of preparation***

The accompanying unaudited condensed consolidated interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP" or "GAAP") for interim financial information and the rules and regulations of the Securities and Exchange Commission (the "SEC").

The accompanying unaudited condensed consolidated interim financial statements contain all normal and recurring adjustments necessary to state fairly the consolidated financial condition, results of operations, comprehensive income, statement of shareholders' equity, and cash flows of the Company for the interim periods presented. Except as otherwise disclosed, all such adjustments consist only of those of a normal recurring nature. Operating results for the three and six months ended June 30, 2025 are not necessarily indicative of the results that may be expected for the current year ending December 31, 2025. The financial data presented herein should be read in conjunction with the audited consolidated financial statements and accompanying notes as of and for the years ended December 31, 2024, and 2023 included in the Annual Report on Form 10-K for the year ended December 31, 2024 (the "2024 Form 10-K").

The preparation of these unaudited condensed consolidated interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ materially from those estimates.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC and the instructions to Form 10-Q.

The unaudited condensed consolidated interim financial statements are presented in United States dollars except as otherwise indicated. All references to C$, CAD$ and CDN$ are to Canadian dollars.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

***Significant Accounting Judgments, Estimates and Assumptions***

The Company's significant accounting policies are described in Note 2 to the Company's 2024 Form 10-K, filed with the SEC, on March 17, 2025. There have been no material changes to the Company's significant accounting policies.

***Reclassification***

Certain reclassifications have been made to the prior period's condensed consolidated interim financial statements and notes to conform to the current year presentation. These reclassifications do not impact the gross margin, profit (loss) from operations, loss before provision for income taxes, and net loss and comprehensive loss presented on the condensed consolidated interim statements of operations and comprehensive loss.

***Revenue***

The Company's revenues are disaggregated as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended** | **Three months ended** | **Six months ended** | **Six months ended** |
| | **June 30, 2025** | **June 30, 2024** | **June 30, 2025** | **June 30, 2024** |
| Dispensary | $67960 | $106093 | $139583 | $213331 |
| Cultivation and wholesale | 18390 | 19097 | 34207 | 34470 |
|  | $86350 | $125190 | $173790 | $247801 |

---

During the three and six months ended June 30, 2025, the Company netted discounts of $22,935 and $45,252, respectively, against the revenues. During the three and six months ended June 30, 2024, the Company netted discounts of $37,505 and $73,884, respectively, against the revenues. Discounts are provided by the Company during promotional days or weekends. Discounts are also provided to employees, seniors, and other categories of customers and may include price reductions and coupons.

**3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; INVENTORY**

Details of the Company's inventory are shown in the table below:

---

| | | |
|:---|:---|:---|
| | **June 30, 2025** | **December 31, 2024** |
| Accessories and supplies | $630 | $1064 |
| Work-in-process - cannabis in cures and final vault | 43340 | 66933 |
| Finished goods - dried cannabis, concentrate and edible products | 26935 | 26519 |
| **Total inventory** | $70905 | $94516 |

---

The inventory values are net of inventory write-downs as a result of obsolescence or unmarketability charged to cost of sales. As a result of certain restructuring efforts, there were write-downs of $9,319 and $10,571 during the three and six months ended June 30, 2025, respectively. As a result of certain restructuring efforts, there were write-downs of $211 and $5,617 during the three and six months ended June 30, 2024.

Inventory is stated net of provision of $2,364 and $5,478 as of June 30, 2025 and December 31, 2024, respectively.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

**4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CURRENT AND LONG-TERM DEBT**

Current and long-term obligations, net, are shown in the table below:

---

| | | |
|:---|:---|:---|
| | **June 30, 2025** | **December 31, 2024** |
| 2026 Notes | $— | $185000 |
| 2027 Convertible Notes |  | 25450 |
| 2025 Convertible Notes |  | 59500 |
| 2028 Notes | 250750 |  |
| 2028 Convertible Notes | 19200 |  |
| Mortgage Note | 40789 | 42923 |
|  | 310739 | 312873 |
| Unamortized debt discount | (11873) | (6156) |
| Unamortized deferred financing costs | (408) | (4744) |
| **Total debt, net** | 298458 | 301973 |
| Less current portion, net\* | (754) | (52461) |
| **Long-term portion** | $297704 | $249512 |

---

\*The current portion of the debt includes scheduled payments on the mortgage notes, convertible notes, and notes, net of corresponding portions of the unamortized debt discount and unamortized deferred financing costs.

The Company was in compliance with all financial covenants and was not in default of any provisions under any of its debt arrangements as of June 30, 2025.

*2026 Notes*

On February 3, 2022, the Company closed a private placement (the "February 2022 Private Placement") of $185,000 aggregate principal amount of 9.50% senior-secured first-lien notes due 2026 (the "2026 Notes") and received aggregate gross proceeds of $153,250. The 2026 Notes were senior secured obligations of the Company and were issued at 100.0% of face value. The 2026 Notes accrued interest in arrears which was payable semi-annually and were scheduled to mature on February 3, 2026, unless earlier redeemed or repurchased. The Company may redeem the 2026 Notes at par, in whole or in part, on or after February 3, 2024, as more particularly described in the fourth supplemental trust indenture governing the 2026 Notes. In connection with the offering of the 2026 Notes, the Company exchanged $31,750 of the Company's existing 13.0% senior secured first-lien notes (the "13.0% Term Debt"), pursuant to private agreements in accordance with the trust indenture, for an equivalent amount of 2026 Notes plus accrued but unpaid interest and any negotiated premium thereon.

The premium and paid interest were paid out of funds raised from the February 2022 Private Placement. The total unamortized debt premium and debt issuance costs of $2,153, related to the modified portion of the 13.0% Term Debt, was being amortized over the term of the 2026 Notes using the effective interest method. The Company incurred $7,189 in creditor fees in connection with the modified 13.0% Term Debt and 2026 Notes and $301 in third-party legal fees related to 2026 Notes, which were capitalized and were being amortized over the term of the 2026 Notes using the effective interest rate method.

On May 29, 2025, the 2026 Notes were exchanged for the 2028 Notes, see 2025 Debt Transactions (the 2028 Notes and the 2028 Convertible Notes). At the time of the exchange, the remaining unamortized debt premium, debt issuance costs, collector fees, and third party legal fees of $2,216 were written off.

*2027 Convertible Notes*

On March 19, 2024, the Company closed a private placement (the "March 2024 Private Placement") of $25,750 aggregate principal amount of 9.0% senior-secured first-lien notes due 2027 (the "2027 Convertible Notes") and received aggregate gross proceeds of $15,600. The 2027 Convertible Notes were senior secured obligations of the Company and were issued at 80.0% of face value. The 2027 Convertible Notes accrued interest in arrears which was payable semi-annually and were scheduled to mature on March 19, 2027. In connection with the offering of the 2027 Convertible Notes, the Company exchanged $5,000 of the Company's existing 6.0% 2025 Convertible Notes. Through June 30, 2025, 983,604 shares were issued to convert $300 principal.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

The principal amount of the 2027 Convertible Notes and the conversion price were denominated in U.S. dollars. As the debt was issued out of the Company's Canadian Holding company, but the functional currency of the Company is US Dollars, the amount of the liability to be settled depends on the applicable foreign exchange rate on the date of settlement. The 2027 Convertible Notes therefore represented an obligation to issue a fixed number of shares for a variable amount of liability. Due to this conversion feature within the 2027 Convertible Notes, the Company was unable to obtain an exception from derivative accounting. Accordingly, this conversion feature was accounted for as an embedded derivative liability and measured at fair value of $2,632 on the date of issuance of debt with a corresponding debt discount and debt issuance costs of $5,952, reflected as a reduction to the carrying value of the 2027 Convertible Notes. The Company fair valued the derivative liability at each balance sheet date. Changes in fair value of the embedded derivative were recognized in the condensed consolidated interim statements of operations and comprehensive loss. The debt discount and debt issuance costs were being amortized over the term of the 2027 Convertible Notes.

On May 29, 2025, the 2027 Convertible Notes were exchanged for the 2028 Notes, see 2025 Debt Transactions (the 2028 Notes and the 2028 Convertible Notes). At the time of the exchange, the remaining unamortized debt discount and debt issuance costs of $3,759 were written off.

*2025 Convertible Notes*

On June 29, 2021, the Company completed an offering of 6.0% Secured Convertible Notes Due 2025 ("2025 Convertible Notes") for an aggregate principal amount of $74.5 million. The 2025 Convertible Notes were senior secured obligations of the Company and accrued interest payable semiannually in arrears and were scheduled to mature on June 29, 2025, unless earlier converted, redeemed, or repurchased. The 2025 Convertible Notes shall be convertible, at the option of the holder, from the date of issuance until the date that is 10 days prior to their maturity date into Common Shares of the Company at a conversion price equal to $6.49 payable on the business day prior to the date of conversion, adjusted downwards for any cash dividends paid to holders of Common Shares and other customary adjustments. The Company may redeem the 2025 Convertible Notes at par, in whole or in part, on or after June 29, 2023, if the volume weighted average price of the Common Shares trading on the Canadian Stock Exchange or Cboe Canada for 15 of the 30 trading days immediately preceding the day on which the Company exercises its redemption right, exceeds 120.0% of the conversion price of the 2025 Convertible Notes at a Redemption Price equal to 100.0% of the principal amount of the 2025 Convertible Notes redeemed, plus accrued but unpaid interest, if any, up to but excluding the Redemption Date.

The 2025 Convertible Notes required interest-only payments until June 29, 2025, at a rate of 6.0% per annum, payable semi-annually in June and December and commencing in December 2021. The 2025 Convertible Notes were schedule to mature on June 29, 2025. The Company incurred financing costs of $3,190 in connection with the 2025 Convertible Notes. The principal amount of the 2025 Convertible Notes and the conversion price were denominated in U.S. dollars. As the debt was issued out of the Company's Canadian Holding company, but the functional currency of the Company is US Dollars, the amount of the liability to be settled depends on the applicable foreign exchange rate on the date of settlement. The 2025 Convertible Notes therefore represent an obligation to issue a fixed number of shares for a variable amount of liability. Due to this conversion feature within the 2025 Convertible Notes, the Company was unable to obtain an exception from derivative accounting. Accordingly, this conversion feature was accounted for as an embedded derivative liability and measured at fair value of $15,099 on the date of issuance of debt with a corresponding debt discount, reflected as a reduction to the carrying value of the 2025 Convertible Notes. The Company fair valued the derivative liability at each balance sheet date. Changes in fair value of the embedded derivative were recognized in the condensed consolidated interim statements of operations and comprehensive loss. The debt discount was amortized over the term of the 2025 Convertible Notes.

On May 29, 2025, the 2025 Convertible Notes were exchanged for the 2028 Notes, see 2025 Debt Transactions (the 2028 Notes and the 2028 Convertible Notes). At the time of the exchange, the remaining unamortized finance costs of $973, were written off.

*January 2024 Debt Exchange*

On January 22, 2024, the Company entered into an exchange agreement, as amended on June 30, 2024 and September 30, 2024 (the "Exchange Agreement"), with certain holders of the Company's 6.0% senior secured 2025 Convertible Notes (the "Holders"), pursuant to which the Company agreed to the repurchase of up to $25

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

million principal amount of the 2025 Convertible Notes in exchange for Common Shares (the "January 2024 Debt Exchange").

Pursuant to the terms of the Exchange Agreement, the Holders shall:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• by January 31, 2024, transfer $5 million principal amount of 2025 Convertible Notes in consideration of Common Shares issued at a price per Common Share equal to the greater of C$0.41 per Common Share and the 12.5% discount to the 5 days volume weighted average price of the Common Shares on Cboe prior to receipt of a Transfer notice;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• provided that the five-day volume weighted average price of the Common Shares on the Exchange is greater than C$0.47 as of the close of trading at 4:01pm on January 31, 2024, transfer $5 million principal amount of 2025 Convertible Notes in consideration of Common Shares issued at the Initial Exchange Price on or prior to February 29, 2024; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• provided that the February Exchange is completed and the daily volume weighted average price of the Common Shares on Cboe is greater than C$0.87 for 5 consecutive trading days, provided that, the trading volume of the Common Shares on Cboe was equal to or greater than 600,000 Common Shares on the applicable trading dates, from the period commencing on January 1, 2024 and ending on June 30, 2025, (which date the parties extended to December 31, 2024), transfer in three separate equal tranches, an aggregate of $15 million principal amount of 2025 Convertible Notes in consideration of Common Shares issued at a price per Common Share equal to the greater of C$0.57 per Common Share and the 12.5% discount to the 5 days volume weighted average price of the Common Shares on Cboe prior to receipt of a Transfer notice, in each case, subject to adjustment in certain instances, on or prior to December 31, 2024.

Through December 31, 2024, $10 million of the potential $25 million exchange had been completed. The term of the Exchange Agreement expired as of January 31, 2025.

*2025 Debt Transaction (the 2028 Notes and the 2028 Convertible Notes)* 

On February 27, 2025, the Company entered into a support agreement (the "Support Agreement") with certain holders (the "Supporting Noteholders") of the aggregate principal amount of issued Senior Notes (as defined below) regarding the exchange of their Senior Notes for new notes having a later maturity date and additional covenants (the "2025 Debt Transaction"). The Senior Notes consist of: (i) the 2025 Convertible Notes; (ii) the 2026 Notes; and (iii) the 2027 Notes (together with the 2025 Convertible Notes and the 2026 Notes, the "Senior Notes"). Under the terms of the 2025 Debt Transaction, among other provisions, the holders of the 2025 Convertible Notes and the 2026 Notes exchanged their Senior Notes for an equal principal amount of 9.25% Senior Secured Notes due December 31, 2028 (subject to two six-month extension options available to the Company upon payment of a 0.5% fee, payable in cash) (the "2028 Notes") and the holders of the 2027 Notes received either (i) an equal principal amount of the 2028 Notes or (ii) if elected, an equal principal amount of newly issued 9.0% convertible notes, which have the same conversion price as the existing 2027 Notes but will the same extended maturity date as the 2028 Notes (the "2028 Convertible Notes", and together with the 2028 Notes, the "New Notes").

The 2028 Notes and 2028 Convertible Notes require interest-only payments until December 31, 2028, payable semi-annually in June and December and commencing in December 2025 until maturity. The Company incurred financing costs of $12,155 in connection with the 2025 Debt Transaction. The principal amount of the 2028 Convertible Notes and the conversion price are denominated in U.S. dollars. As the debt was issued out of the Company's Canadian Holding company, but the functional currency of the Company is US Dollars, the amount of the liability to be settled depends on the applicable foreign exchange rate on the date of settlement. The 2028 Convertible Notes therefore represent an obligation to issue a fixed number of shares for a variable amount of liability. Due to this conversion feature within the 2028 Convertible Notes, the Company is unable to obtain an exception from derivative accounting. Accordingly, this conversion feature was accounted for as an embedded derivative liability and measured at fair value of $230 on the date of issuance of debt with a corresponding debt discount, reflected as a reduction to the carrying value of the 2028 Convertible Notes. The Company fair values the derivative liability at each balance sheet date. Changes in fair value of the embedded derivative are recognized in the condensed consolidated interim statements of operations and comprehensive loss. The debt financing costs are amortized over the term of the 2028 Notes and 2028 Convertible Notes.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

In addition, as part of the 2025 Debt Transaction, the Company issued 118,209,105 warrants to the Company shareholders on a pro rata basis, see Note 10 Warrants.

The 2028 Notes and 2028 Convertible Notes are secured by a first-priority security interest in all present and after-acquired personal property of the Company, including a pledge of the Equity Interests owned by the Issuer and each Guarantor; and a collateral assignment of leases in respect of certain leasehold property and all of the Company's interests therein as defined in the Amended and Restated Trust Indenture.

The Company completed its 2025 Debt Transaction effective May 29, 2025 following receipt of court approval.

*Mortgages*

In December 2021, the Company entered into a term loan and security agreement with a bank. The agreement provides for a $20,000 mortgage on real property in New York and carries interest at a variable rate per annum equal to the Wall Street Prime Rate ("Index") plus 2.25%. The debt is repayable in 59 monthly installments and a final balloon payment due on January 1, 2027, which is estimated at $17,920 as of June 30, 2025. In connection with this mortgage, the Company incurred financing costs of $655.

In June 2022, the Company entered into a term loan and security agreement with a bank. The agreement provides for a $16,500 mortgage on real property in New Jersey and carries interest at a variable rate per annum equal to the Index plus 2.25%. The debt is repayable in 59 monthly installments and a final balloon payment due on July 15, 2027, which is estimated at $15,549 as of June 30, 2025. In connection with this mortgage, the Company incurred financing costs of $209.

On August 10, 2023, the Company entered into two term loans and security agreements with a bank as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The first agreement provides for a $6,250 mortgage on real property in Maryland and carries interest at a variable rate per annum equal to the Index plus 2.25%. The debt is repayable in 59 monthly installments and matures in August 2028. In connection with this mortgage, the Company incurred financing costs of $195 and netted $2,903 after the repayment of a prior outstanding mortgage on the property.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The second agreement provides for a $1,800 mortgage on real property in Delaware and carries interest at a variable rate per annum equal to the Index plus 2.25%. The debt is repayable in 59 monthly installments and matures in August 2028. In connection with this mortgage, the Company incurred financing costs of $77 and netted $1,723. The mortgage was paid in full on January 15, 2025 with the sale of the property.

Total interest and amortization expense on the Company's debt obligations during the three and six months ended June 30, 2025 and 2024 are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended** | **Three months ended** | **Six months ended** | **Six months ended** |
| | **June 30, 2025** | **June 30, 2024** | **June 30, 2025** | **June 30, 2024** |
| Interest expense on debt | $6929 | $7398 | $13980 | $14713 |
| Amortization of debt discount | 4621 | 1500 | 6156 | 2505 |
| Amortization of debt issuance costs | 3514 | 950 | 4522 | 1802 |
| Other interest expense (income), net | (379) | (132) | (819) | (270) |
| **Total interest expense, net** | $14685 | $9716 | $23839 | $18750 |

---

The weighted average interest rate on the Company's indebtedness was 9.23%.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

**5. PROPERTY AND EQUIPMENT**

Details of the Company's property and equipment and related depreciation expense are summarized in the tables below:

---

| | | |
|:---|:---|:---|
| | **June 30, 2025** | **December 31, 2024** |
| Land and buildings | $109052 | $115277 |
| Furniture and fixtures | 4930 | 6804 |
| Equipment | 30349 | 34367 |
| Computers and software | 2019 | 2363 |
| Leasehold improvements | 148627 | 155529 |
| Construction in process | 5556 | 6565 |
| &nbsp;&nbsp;&nbsp;**Total property and equipment, gross** | 300533 | 320905 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less: accumulated depreciation | (88091) | (92509) |
| &nbsp;&nbsp;&nbsp;**Total property and equipment, net** | $212442 | $228396 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended** | **Three months ended** | **Six months ended** | **Six months ended** |
| | **June 30, 2025** | **June 30, 2024** | **June 30, 2025** | **June 30, 2024** |
| Total depreciation expense for three and six months ended | $4566 | $8314 | $9211 | $16652 |
| Included in: |  |  |  |  |
| Costs of sales related to inventory production | $3008 | $5216 | $6007 | $10417 |
| Selling, general and administrative expenses | $1558 | $3098 | $3204 | $6235 |

---

**6. PREPAID EXPENSES AND OTHER CURRENT ASSETS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Details of the Company's prepaid expenses and other current assets are summarized in the table below:

---

| | | |
|:---|:---|:---|
| | **June 30, 2025** | **December 31, 2024** |
| Prepaid expenses | $9085 | $8719 |
| Short term deposits | 1033 | 914 |
| Other current assets | 3163 | 1932 |
| Excise and sales tax receivable | 29 | 229 |
| **Prepaid expenses and other current assets** | $13310 | $11794 |

---

**7. OTHER NON-CURRENT ASSETS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Details of the Company's other non-current assets are summarized in the table below:

---

| | | |
|:---|:---|:---|
| | **June 30, 2025** | **December 31, 2024** |
| Long term deposits | $7376 | $8604 |
| Long term tax receivable | 1608 | 1712 |
| Investment in affiliates | 775 | 775 |
| Restricted cash | 3135 | 4323 |
| **Other non-current assets** | $12894 | $15414 |

---

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

**8. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Details of the Company's accrued expenses and other current liabilities are summarized in the table below:

---

| | | |
|:---|:---|:---|
| | **June 30, 2025** | **December 31, 2024** |
| Taxes - property and other | $1706 | $4912 |
| Other accrued expenses | 6269 | 13477 |
| Payroll liabilities | 7917 | 10709 |
| Other current liabilities | 2659 | 3741 |
| **Accrued expenses and other current liabilities** | $18551 | $32839 |

---

**9. SHAREHOLDERS' EQUITY**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company had the following activity during the three and six months ended June 30, 2025:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cancelled 93,662 of Restricted Stock Units (RSUs) during the six months ended June 30, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Issued 6,872,394 common shares upon vesting of Restricted Stock Units (RSUs).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Issued 19,328,305 common shares in connection with the 2028 Convertible Notes.

**10. WARRANTS**

As of June 30, 2025 and December 31, 2024, outstanding warrants to purchase Common Shares consisted of the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **June 30, 2025** | **June 30, 2025** | **December 31, 2024** | **December 31, 2024** |
|<br>**Expiration** | **Number of Shares<br>Issued and Exercisable** | **Exercise Price**<br>**(Canadian Dollars)** | **Number of Shares<br>Issued and Exercisable** | **Exercise Price**<br>**(Canadian Dollars)** |
| September 21, 2026 | 11122105 | $1.96 | 11122105 | $1.96 |
| October 1, 2025 | 648783 | 8.12 | 648783 | 8.12 |
| May 29, 2027 | 118246947 | $0.14 |  | $— |
|  | 130017835 | $0.34 | 11770888 | $2.30 |

---

Warrant activity for the six months ended June 30, 2025 and 2024 are summarized in the table below:

---

| | | |
|:---|:---|:---|
| | **Number of**<br>**Warrants**  | **Weighted average<br>exercise price<br>(Canadian Dollars)** |
| **Balance as of December 31, 2023** | 17165833 | $4.83 |
| Issued |  |  |
| Expired |  |  |
| **Balance as of June 30, 2024** | 17165833 | $4.83 |
| **Balance as of December 31, 2024** | 11770888 | $2.30 |
| Issued | 118246947 | 0.14 |
| Expired |  |  |
| **Balance as of June 30, 2025** | 130017835 | $0.34 |

---

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

**11. LOSS PER SHARE**

Basic and diluted net loss per share attributable to the Company was calculated as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended** | **Three months ended** | **Six months ended** | **Six months ended** |
| | **June 30, 2025** | **June 30, 2024** | **June 30, 2025** | **June 30, 2024** |
| Numerator: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net loss | $(77386) | $(13643) | $(109592) | $(48211) |
| &nbsp;&nbsp;&nbsp;Less: net profit attributable to non-controlling interests | 495 | 698 | 493 | 1203 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss attributable to shareholders | $(77881) | $(14341) | $(110085) | $(49414) |
| Denominator: |  |  |  |  |
| Weighted average shares outstanding - basic and diluted | 484713110 | 460653957 | 478894930 | 453143911 |
| Loss per share - basic and diluted | $(0.16) | $(0.03) | $(0.23) | $(0.11) |

---

Certain share-based equity awards were excluded from the computation of dilutive loss per share because inclusion of these awards would have had an anti-dilutive effect.

**12. COMMITMENTS AND CONTINGENCIES** 

In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners, and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and senior management that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited.

Additionally, the Company may be contingently liable with respect to other claims incidental to the ordinary course of its operations. Except as described below, in the opinion of management, and based on management's consultation with legal counsel, the ultimate outcome of such other matters will not have a materially adverse effect on the Company. Accordingly, no provision has been made in these consolidated financial statements for losses, if any, which might result from the ultimate disposition of these matters should they arise.

Murchinson Ltd., an investment manager of holders of 2025 Convertible Notes and 2027 Convertible Notes, subsequently exchanged for 2028 Notes (the "Applicant"), filed an application in the Ontario Superior Court of Justice (Commercial List) (the "Court") on March 27, 2025, opposing the 2025 Debt Transaction and claiming the transaction was oppressive to the Applicant. The application filed by the Applicant also claimed breach of contract and civil conspiracy. The Applicant sought from the court, among other forms of relief, that the 2025 Debt Transaction be declared unlawful under the terms of the Canadian Business Corporations Act, an award of unspecified damages, and recovery of costs. By order dated May 21, 2025, the Court ruled in favor of the Company and the 2025 Debt Transaction was subsequently closed. Murchinson Ltd. has filed appeals to the Court of Appeal for Toronto that are currently pending.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

**13. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS**

*<u>Fair Value Measurements</u>* 

The following table presents the Company's financial instruments that are measured at fair value on a recurring basis:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Level 1** | **Level 2** | **Level 3** | **Total** |
| **June 30, 2025** | | | | |
| Investment securities | $3860 | $— | $— | $3860 |
| Total assets | $3860 | $— | $— | $3860 |
| Derivative liabilities | $— | $— | $(980) | $(980) |
| Total liabilities | $— | $— | $(980) | $(980) |
| **December 31, 2024** |  |  |  |  |
| Investment securities | $11880 | $— | $— | $11880 |
| Total assets | $11880 | $— | $— | $11880 |
| Derivative liability | $— | $— | $(621) | $(621) |
| Total liabilities | $— | $— | $(621) | $(621) |

---

During the period included in these financial statements, there were no transfers of amounts between levels.

Level 1 investment securities are stated at observable inputs such as quoted prices in active markets.

The following table summarizes the valuation techniques and key inputs used in the fair value measurement of Level 3 financial instruments:

---

| | | | |
|:---|:---|:---|:---|
| **Financial asset/financial<br>liability** | **Valuation techniques** | **Significant unobservable<br>inputs** | **Relationship of unobservable<br>inputs to fair value** |
| Derivative liability | Market approach | Conversion period | Increase or decrease in conversion period will result in an increase or decrease in fair value |

---

There has been no change in the valuation methodology for the six months ended June 30, 2025. The carrying amounts of cash and restricted cash, accounts receivable, other current assets, accounts payable, accrued expenses, other current liabilities, the current portion of long-term debt, and lease liabilities as of June 30, 2025 and December 31, 2024 approximate their fair values because of the short-term nature of these items and are not included in the table above. The Company's other long-term liabilities and long-term debt approximate fair value due to the market rate of interest used on initial recognition.

In addition to the disclosures for assets and liabilities required to be measured at fair value at the balance sheet date, companies are required to disclose the estimated fair values of all financial instruments, even if they are not presented at their fair value on the consolidated balance sheet. The fair values of financial instruments are estimates based upon market conditions and perceived risks as of June 30, 2025 and December 31, 2024. These estimates require management's judgment and may not be indicative of the future fair values of the assets and liabilities.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

**14. INTANGIBLE ASSETS** 

Intangible assets consist of the following:

---

| | | |
|:---|:---|:---|
| | **June 30, 2025** | **December 31, 2024** |
| Licenses | $99163 | $109973 |
| Trademarks | 23075 | 23810 |
| Customer relationships | 15264 | 15263 |
| Total intangible assets | 137502 | 149046 |
| Less: accumulated amortization | (96015) | (97797) |
| Total intangible assets, net | $41487 | $51249 |

---

Amortization expense for the three and six months ended June 30, 2025 and 2024 are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended** | **Three months ended** | **Six months ended** | **Six months ended** |
| | **June 30, 2025** | **June 30, 2024** | **June 30, 2025** | **June 30, 2024** |
| Amortization expense | $2203 | $2904 | $4605 | $6165 |

---

**15. SELLING, GENERAL AND ADMINISTRATIVE EXPENSES**

Selling, general and administrative expenses are summarized in the table below:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended** | **Three months ended** | **Six months ended** | **Six months ended** |
| | **June 30, 2025** | **June 30, 2024** | **June 30, 2025** | **June 30, 2024** |
| Salaries and benefits | $14000 | $13362 | $30439 | $39136 |
| Professional fees | 2025 | 2392 | 3814 | 4948 |
| Depreciation and amortization | 4443 | 6685 | 9174 | 13765 |
| Operating facilities costs | 7440 | 10590 | 15142 | 21670 |
| Operating office and general expenses | 3750 | 5335 | 8790 | 10707 |
| Advertising and promotion | 1325 | 802 | 2354 | 1807 |
| Other fees and expenses | 7 | 880 | 528 | 1286 |
| **Total selling, general and administrative expenses** | $32990 | $40046 | $70241 | $93319 |

---

**16. OTHER (INCOME) EXPENSE, NET**

Other (income) expense, net is summarized in the table below:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended** | **Three months ended** | **Six months ended** | **Six months ended** |
| | **June 30, 2025** | **June 30, 2024** | **June 30, 2025** | **June 30, 2024** |
| Change in fair value of the derivative liability | $359 | $(18) | $359 | $2329 |
| Change in fair value of investments | 713 |  | 6520 |  |
| Restructuring expense | (1592) | 1966 | 1104 | 4542 |
| Other (income) /expense, net | 37 | (907) | (1830) | (994) |
| Adjustment for held-for-sale | (651) |  | 2868 |  |
| Loss on disposal | 4089 | 413 | 7327 | 624 |
| Rental income | (24) | (58) | (48) | (115) |
| **Total other expense, net** | $2931 | $1396 | $16300 | $6386 |

---

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

During the six months ended June 30, 2025 and 2024, the Company recorded $1,104 and $4,542 in restructuring expense, respectively. As of June 30, 2025 and 2024, the balance outstanding on the Company's restructuring reserve was $1,267 and $$4,731 respectively.

Loss on disposal arose primarily on the divestitures of a California store and related real estate as delineated in Note 17 below, and is stated net of any gains and losses attributable to minority investors.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

&nbsp;&nbsp;&nbsp;&nbsp;**17. DIVESTITURE**

*Utah Business Divestiture* 

On October 6, 2023, the Company entered into a definitive agreement, subject to closing conditions, to dispose of its Utah operations (the "Utah Business") which are considered non-core and comprised of one dispensary and one cultivation facility. The Utah Business was divested for gross proceeds of approximately $6.5 million, with approximately $3.9 million due on closing of the transaction, and a $2.6 million Seller note payable to the Company not later than July 2025. The sale of the Utah assets was completed on March 7, 2024 and the Company received an early settlement of the Seller note on April 1, 2025 in the amount of $2.0 million.

*Arizona Divestiture*

On July 29, 2024, the Company entered into definitive agreements, subject to closing conditions, to dispose of its Arizona operations (the "Arizona Business") which are comprised of two dispensaries and one cultivation / manufacturing facility. The Arizona Business was divested for gross proceeds of $15 million, with approximately all $15 million which was received on signing of the definitive agreement.

*Eastern Virginia Divestiture*

On July 29, 2024, the Company entered into a definitive agreement, subject to closing conditions, to dispose of a portion of its Virginia operations (the "East Virginia Business") which are comprised of six dispensaries and one cultivation / manufacturing facility. The East Virginia Business was divested for gross proceeds of $90 million, consisting of approximately $20 million in cash, $40 million of equity in the Buyer, Verano Holdings Corp., due on closing of the transaction, and a $30 million seller note payable to the Company over a 14 month period.

In May 2025, the Company reached an agreement on the early settlement of the balance on this seller note Receivable, with a $10.0 million one-time payment made as full and early settlement of the note. Accordingly, there is a $0 balance receivable on the note as of June 30, 2025.

*Florida Business Divestiture*

On November 7, 2024, the Company sold the majority of its Florida operations (the "Florida Business") through the sale of fourteen dispensaries and two cultivation / manufacturing facilities for gross proceeds of $5 million, consisting of approximately $3 million in cash and $2 million of promissory note. Following the sale of the Florida Business, the Company had one license and one cultivation facility in the state, neither of which remained in active operation. On April 17, 2025, the Company sold the license for $5 million in cash, with the potential for an additional $2.5 million contingent payment in the event of an adult use program in the state.

*Milford, Delaware Divestiture*

On January 15, 2025, the Company sold its Milford II cultivation property, which had not yet been developed and was a non-operating asset. Gross proceeds from the sale were $3.37 million, approximately $1.8 million of which was used to fully settle the outstanding mortgage on the property.

*North Hollywood, California Divestiture*

On March 18, 2025, the Company entered into a definitive agreement, subject to closing conditions, to dispose of its North Hollywood dispensary (the "NoHo store"). The NoHo store was divested for gross proceeds of approximately $1.375 million, with approximately $715 thousand paid up-front and the balance due on completion of closing conditions.

*DeSoto, California Divestiture*

On April 3, 2025, the Company entered into a definitive agreement, subject to closing conditions, to dispose of its DeSoto, San Diego, dispensary (the "DeSoto store"). The DeSoto store was divested for gross proceeds of approximately $1 million, with approximately $500 thousand paid up-front and the balance due on completion of closing conditions.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

*THC, California Divestiture*

On April 15, 2025, the Company entered into a definitive agreement, subject to closing conditions, to dispose of its THC, San Diego, dispensary (the "THC store"). The THC store was divested for gross proceeds of approximately $1 million, with approximately $500 thousand paid up-front and the balance due on completion of closing conditions.

*Florida License Divestiture*

On April 17, 2025, the Company entered into a definitive agreement, subject to closing conditions, to dispose of its Florida paper License (the "Florida License"). The Florida License store was divested for gross proceeds of approximately $5 million, with approximately $4 million paid up-front and the balance due on completion of closing conditions.

The table below summarizes the operating results of the disposed of business for the three and six months ended June 30, 2025, and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended** | **Three months ended** | **Six months ended** | **Six months ended** |
| | **June 30, 2025** | **June 30, 2024** | **June 30, 2025** | **June 30, 2024** |
| **Utah** | | | | |
| Revenue | $— | $— | $— | $943 |
| Expense | $— | $— | $— | $822 |
| **California** |  |  |  |  |
| Revenue | $131 | $— | $4575 | $— |
| Expense | $325 | $— | $5083 | $— |
| **Total** |  |  |  |  |
| Revenue | $131 | $— | $4575 | $943 |
| Expense | $325 | $— | $5083 | $822 |

---

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

&nbsp;&nbsp;&nbsp;&nbsp;**18. NET ASSETS HELD FOR SALE**

During 2023, the Company committed to a plan to sell its Utah operations. Accordingly, certain of the assets and liabilities held by the Company's Utah subsidiary were presented as a disposal group held for sale on the consolidated balance sheet as of December 31, 2023. The sale of the Utah assets was completed on March 7, 2024.

On November 7, 2024, the Company sold its Florida Business through the sale of fourteen dispensaries and two cultivation / manufacturing facilities for gross proceeds of $5 million, consisting of approximately $3 million in cash and $2 million of promissory note. Following the sale of the Florida Business, the Company had one license and one cultivation facility in the state, neither of which remained in active operation. On April 17, 2025, the Company sold the license for $5 million in cash, with the potential for an additional $2.5 million contingent payment in the event of an adult use program in the state. The company continues to market for future disposition of a cultivation facility in Florida. On April 25, 2025, the Company entered into a definitive agreement, subject to closing, to sell the cultivation site for $11 million.

In early 2025, the Company committed to a plan to sell its Illinois operations (the "Illinois Business") which are comprised of two dispensaries and one cultivation / manufacturing facility.

In early 2025, the Company also committed to a plan to sell its remaining California operations (the "remaining California Business") which is comprised of three dispensaries and one cultivation / manufacturing facility. During the six months ended June 30, 2025, the Company disposed of two of the three dispensaries, see Note 17 Divestitures (DeSoto and THC). In July 2025, the cultivation / manufacturing facility was divested, see Note 19 Subsequent Events.

The planned disposals as of June 30, 2025 did not represent a strategic shift of the Company that had or will have a major effect on the Company's operations and financial results. Accordingly, the operations were not segregated and were presented as continuing operations in the condensed consolidated interim statements of operations and comprehensive loss as of June 30, 2025 and December 31, 2024. The disposal group was stated at fair value less costs to sell and comprised the following assets and liabilities:

---

| | | |
|:---|:---|:---|
| | **June 30, 2025** | **December 31, 2024** |
| Cash | $— | $239 |
| Accounts receivable | 1081 | 34 |
| Inventory | 7413 | 364 |
| Prepaid expenses and other current assets | 893 | 381 |
| Property, plant and equipment | 13149 | 9516 |
| Right-of-use assets | 24282 | 2364 |
| Right of use assets - finance leases, net | 104 | 102 |
| Intangible assets, net | 1787 | 4778 |
| **Assets held for sale** | $48709 | $17778 |
| Accounts payable and other liabilities | $(6109) | $(104) |
| Lease liabilities | (26377) | (2552) |
| **Liabilities held for sale** | $(32486) | $(2656) |

---

The non-recurring fair value measurement for the disposal group has been categorized as a Level 3 fair value utilizing Level 3 inputs and using a market approach, based on available data for transactions in the region and discussions with potential acquirers.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

**19. SUBSEQUENT EVENT** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• On or about July 2, 2025, the Company entered into definitive agreements to divest its Balboa, CA manufacturing facility for approximately $738 thousand in gross proceeds

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• On July 16, 2025, the Compensation Committee of the Board of Directors (the "Board") of The Cannabist Company Holdings Inc. (the "Company") approved a Transaction Bonus Plan (the "Bonus Plan"). Under the Bonus Plan, the Company will establish a bonus pool (the "Bonus Pool"). The size of the Bonus Pool will be 1.50% of the transaction value, as defined and determined by the Compensation Committee, for divestitures or other strategic transactions, not previously approved by the Board, that are closed while the Bonus Plan is in effect. The Bonus Pool, if qualifying divestitures or strategic transactions are completed, will be funded directly from funds available for general corporate purposes and will be capped at $5,000,000. Certain key employees of the Company who are designated as participants will be eligible to be paid a bonus or bonuses based on individual allocations of the Bonus Pool, as determined by the Compensation Committee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• On July 17, 2025, Jesse Channon, the Company's President, entered into a second amended and restated employment agreement with the Company pursuant to which the termination and change of control provisions of Mr. Channon's amended and restated employment agreement with Company, dated March 11, 2024, were amended to provide that if Mr. Channon resigns for "Good Reason" (as defined in the Channon A&R Employment Agreement), Mr. Channon will receive an amount equal to 18 months of his then current Base Salary plus target bonus, less all applicable withholdings and deductions, paid over an 18-month period, and the Company shall pay its share of Mr. Channon's health insurance premiums to continue Mr. Channon's health insurance coverage for 18 months beyond the termination date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• On or about August 4, 2025, the Company entered into definitive agreements to divest three dispensaries in Pennsylvania for $10 million in gross proceeds and also signed a supply agreement with the same buyer.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.**

*This management's discussion and analysis ("MD&A") of the financial condition and results of operations of The Cannabist Company Holdings Inc. ("The Cannabist Company", the "Company", "us", "our" or "we") is supplemental to, and should be read in conjunction with, The Cannabist Company's unaudited condensed consolidated interim financial statements and the accompanying notes for the three and six months ended June 30, 2025 and 2024. Except for historical information, the discussion in this section contains forward-looking statements that involve risks and uncertainties. Future results could differ materially from those discussed below for many reasons, including the risks described in "Disclosure Regarding Forward-Looking Statements," "Item 1A-Risk Factors" and elsewhere in the Company's 2024 Form 10-K filed with the SEC on March 17, 2025 and subsequent securities filings.*

*The Cannabist Company's financial statements are prepared in accordance with generally accepted accounting principles in the United States of America ("US GAAP"). Financial information presented in this MD&A is presented in thousands of United States dollars ("$" or "US$"), unless otherwise indicated.*

**OVERVIEW OF THE CANNABIST COMPANY**

The Cannabist Company, formerly known as Columbia Care, is one of the most experienced cultivators, manufacturers and providers of cannabis products and related services, with licenses in 12 U.S. jurisdictions. The Company operates 71 facilities including 53 dispensaries and 18 cultivation and manufacturing facilities, including those under development. Columbia Care, now The Cannabist Company, is one of the original multi-state providers of cannabis in the U.S. and now delivers industry-leading products and services to both the medical and adult-use markets. In 2021, the Company launched Cannabist, its retail brand, creating a national dispensary network that leverages proprietary technology platforms. The company offers products spanning flower, edibles, oils and tablets, and manufactures popular brands including dreamt, Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, and Amber.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

**SELECTED FINANCIAL INFORMATION**

The following tables set forth selected consolidated financial information derived from our unaudited condensed consolidated interim financial statements and the respective accompanying notes prepared in accordance with U.S. GAAP.

During the periods discussed herein, our accounting policies have remained consistent. The selected and summarized consolidated financial information below may not be indicative of our future performance.

Statement of Operations:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended** | **Three months ended** | **Three months ended** | **Three months ended** | **Six months ended** | **Six months ended** | **Six months ended** | **Six months ended** |
| | **June 30, 2025** | **June 30, 2024** | **$ Change** | **% Change** | **June 30, 2025** | **June 30, 2024** | **$ Change** | **% Change** |
| Revenues | $86350 | $125190 | $(38840) | (31)% | $173790 | $247801 | $(74011) | (30)% |
| Cost of sales related to inventory production | (69197) | (77138) | 7941 | (10)% | (127352) | (157212) | 29860 | (19)% |
| Gross profit | 17153 | 48052 | (30899) | (64)% | 46438 | 90589 | (44151) | (49)% |
| Fixed asset impairment |  |  |  | —% | (193) |  | (193) | —% |
| Selling, general and administrative expenses | (32990) | (40046) | 7056 | (18)% | (70241) | (93319) | 23078 | (25)% |
| Profit (loss) from operations | (15837) | 8006 | (23843) | (298)% | (23996) | (2730) | (21266) | 779% |
| Other income / (expense), net | (18328) | (12007) | (6321) | 53% | (41581) | (26971) | (14610) | 54% |
| Income tax expense | (43221) | (9642) | (33579) | 348% | (44015) | (18510) | (25505) | 138% |
| Net loss | (77386) | (13643) | (63743) | 467% | (109592) | (48211) | (61381) | 127% |
| Net profit attributable to non-controlling interests | 495 | 698 | (203) | (29)% | 493 | 1203 | (710) | (59)% |
| Net loss attributable to The Cannabist Company Holdings Inc. | (77881) | (14341) | (63540) | 443% | (110085) | (49414) | (60671) | 123% |
| Loss per share attributable to The Cannabist Company Holdings Inc.—based and diluted | $(0.16) | $(0.03) | $(0.13) | 416% | $(0.23) | $(0.11) | $(0.12) | 111% |
| Weighted average number of shares outstanding—basic and diluted | 484713110 | $460653957 |  |  | 478894930 | $453143911 |  |  |

---

Summary of Balance Sheet items:

---

| | | |
|:---|:---|:---|
| | **June 30, 2025** | **December 31, 2024** |
| Total Assets | $563838 | $696173 |
| Total Liabilities | $702684 | $726232 |
| Total Long-Term Liabilities | $523677 | $497522 |
| Total Equity | $(138846) | $(30059) |

---

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

**RESULTS OF OPERATIONS**

***Comparison of the three and six months ended June 30, 2025 and 2024***

The following table summarizes our results of operations for the three months ended June 30, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended** | **Three months ended** | **Three months ended** | **Three months ended** |
| | **June 30, 2025** | **June 30, 2024** | **$ Change** | **% Change** |
| Revenues | $86350 | $125190 | $(38840) | (31)% |
| Cost of sales related to inventory production | (69197) | (77138) | 7941 | (10)% |
| Gross profit | 17153 | 48052 | (30899) | (64)% |
| Selling, general and administrative expenses | (32990) | (40046) | 7056 | (18)% |
| Profit (loss) from operations | (15837) | 8006 | (23843) | (298)% |
| Other income / (expense), net | (18328) | (12007) | (6321) | 53% |
| Income tax expense | (43221) | (9642) | (33579) | 348% |
| Net loss | (77386) | (13643) | (63743) | 467% |
| Net profit attributable to non-controlling interests | 495 | 698 | (203) | (29)% |
| Net loss attributable to The Cannabist Company Holdings Inc. | $(77881) | $(14341) | $(63540) | 443% |
| Loss per share attributable to The Cannabist Company Holdings Inc.—based and diluted | $(0.16) | $(0.03) | $(0.13) | 416% |
| Weighted average number of shares outstanding—basic and diluted | 484713110 | 460653957 |  |  |

---

*Revenues*

The decrease in revenue of $38,840 for the three months ended June 30, 2025, as compared to the prior year period, was driven by the net decline in revenue of $10,902 in our existing retail and wholesale operations and a decline of $30,387 from the sale or closure of certain operations. This was partly offset by changes in regulation to adult use which contributed to a revenue growth of $2,449 during the three months ended June 30, 2025, as compared to the prior period.

*Cost of Sales* 

The decrease in cost of sales of $7,941 for the three months ended June 30, 2025, as compared to the prior year period, was driven by a cost of sales decrease from the sale or closure of certain operations of $17,435. This was partly offset by an increase of $9,494 in our existing retail and wholesale operations, including from inventory impairment.

*Gross Profit* 

The decrease in gross profit of $30,899 for the three months ended June 30, 2025, as compared to the prior year period, was directly attributable to the decline in revenues and the decline in cost of sales as described above.

*Operating Expenses*

The decrease of $7,065 in operating expenses for the three months ended June 30, 2025, as compared to the prior year period, was primarily attributable to decreases in operating facilities costs of $3,150, depreciation and amortization of $2,242, operating office and general expenses of $1,585, professional fees of $367, and other fees and expenses of $873. This was partially offset by increases in salaries and benefits of expenses of $638 and advertisement and promotion expense of $523 for the three months ended June 30, 2025.

*Other Income / (expense), Net*

The increase in other expenses, net of $6,321 for the three months ended June 30, 2025, as compared to the prior year period, was primarily due to increases in interest expense, net of $4,969, loss on disposal group of $3,676, change in fair value of investments of $713, change in fair value of the derivative liability of $377, and a decrease in rental income of $34. This was partially offset by decreases in restructuring expense of $3,558, loss on held for sale of $651, and interest expense on leases of $183.

*Provisions for Income Taxes*

The Company recorded income tax expense of $43,221 for the three months ended June 30, 2025, as compared to an income tax expense of $9,642 for the three months ended June 30, 2024.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

The following table summarizes our results of operations for the six months ended June 30, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Six months ended** | **Six months ended** | **Six months ended** | **Six months ended** |
| | **June 30, 2025** | **June 30, 2024** | **$ Change** | **% Change** |
| Revenues | $173790 | $247801 | $(74011) | (30)% |
| Cost of sales related to inventory production | (127352) | (157212) | 29860 | (19)% |
| Gross profit | 46438 | 90589 | (44151) | (49)% |
| Fixed asset impairment | (193) |  | (193) | —% |
| Selling, general and administrative expenses | (70241) | (93319) | 23078 | (25)% |
| Loss from operations | (23996) | (2730) | (21266) | 779% |
| Other income / (expense), net | (41581) | (26971) | (14610) | 54% |
| Income tax expense | (44015) | (18510) | (25505) | 138% |
| Net loss | (109592) | (48211) | (61381) | 127% |
| Net profit attributable to non-controlling interests | 493 | 1203 | (710) | (59)% |
| Net loss attributable to The Cannabist Company Holdings Inc. | $(110085) | $(49414) | $(60671) | 123% |
| Loss per share attributable to The Cannabist Company Holdings Inc.—based and diluted | $(0.23) | $(0.11) | $(0.12) | 111% |
| Weighted average number of shares outstanding—basic and diluted | 478894930 | 453143911 |  |  |

---

*Revenues*

The decrease in revenue of $74,011 for the six months ended June 30, 2025, as compared to the prior year period, was driven by the net

decline in revenue of $23,854 in our existing retail and wholesale operations and a decline of $56,319 from the sale or closure of certain

operations. This was partly offset by changes in regulation to adult use which contributed to a revenue growth of $6,162 during the six

months ended June 30, 2025, as compared to the prior period

*Cost of Sales* 

The decrease in cost of sales of $29,860 for the six months ended June 30, 2025, as compared to the prior year period, was driven by the sale or closure of certain operations of $32,238. This was partly offset by an increase of $2,378 in our existing retail and wholesale operations, including from inventory impairment, as compared to the prior period.

*Gross Profit* 

The decrease in gross profit of $44,151 for the six months ended June 30, 2025, as compared to the prior year period, was directly attributable to the decline in revenues and the decline in cost of sales as described above.

*Operating Expenses*

The decrease of $23,078 in operating expenses for the six months ended June 30, 2025, as compared to the prior year period, was primarily attributable to decreases in salary and benefits expenses of $8,697, operating facilities costs of $6,528, depreciation and amortization of $4,591, operating office and general expenses of $1,917, professional fees of $1,134, and other fees and expenses of $758. This was partially offset by an increase in advertisement and promotion expense of $547 for the six months ended June 30, 2025.

*Other Income / (expense), Net*

The increase in other expenses, net of $14,610 for the six months ended June 30, 2025, as compared to the prior year period, was primarily due to a increases in change in fair value of investments of $6,520, loss on held for sale of $2,868, loss on disposal group of $6,703, interest expense, net of $5,089, and a decrease in rental income of $67. This was partially offset by decreases change in fair value of the derivative liability of $1,970, restructuring expense of $3,438, interest on leases of $393, and other income (expense), net of $836.

*Provisions for Income Taxes* The Company recorded income tax expense of $44,015 for the six months ended June 30, 2025, as compared to an income tax expense of $18,510 for the six months ended June 30, 2024.

**Non-GAAP Measures**

We use certain non-GAAP measures, referenced in this MD&A. These measures are not recognized measures under GAAP and do not have a standardized meaning prescribed by GAAP and therefore may not be comparable to similar measures presented by other companies. Accordingly, these measures should not be considered in isolation from nor as a substitute for our financial information reported under GAAP. We use non-GAAP measures including EBITDA, Adjusted EBITDA and Adjusted EBITDA margin which may be calculated

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

differently by other companies. These non-GAAP measures and metrics are used to provide investors with supplemental measures of our operating performance and liquidity and thus highlight trends in our business that may not otherwise be apparent when relying solely on GAAP measures. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for, or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented. We also recognize that securities analysts, investors, and other interested parties frequently use non-GAAP measures in the evaluation of companies within our industry. Finally, we use non-GAAP measures and metrics in order to facilitate evaluation of operating performance comparisons from period to period, to prepare annual operating budgets and forecasts and to determine components of executive compensation.

The following table provides a reconciliation of net loss for the period to EBITDA and Adjusted EBITDA for the three and six months ended June 30, 2025, and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended** | **Three months ended** | **Six months ended** | **Six months ended** |
|  | **June 30, 2025** | **June 30, 2024** | **June 30, 2025** | **June 30, 2024** |
| Net loss | $(77386) | $(13643) | $(109592) | $(48211) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax | 43221 | 9642 | 44015 | 18510 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 8205 | 13583 | 16851 | 27547 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net and debt amortization | 18029 | 13121 | 30588 | 25601 |
| EBITDA (Non-GAAP measure) | (7931) | 22703 | (18138) | 23447 |
| Adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation | 643 | (8144) | 935 | (4962) |
| &nbsp;&nbsp;&nbsp;&nbsp;Legal settlement |  | (1108) |  | (1108) |
| &nbsp;&nbsp;&nbsp;&nbsp;Fair-value changes on investments and derivative liabilities | 1072 | (18) | 6879 | 2329 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments for acquisition and other non-core costs | 12853 | 1726 | 15608 | 7971 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring expense | (1592) | 1966 | 1104 | 4542 |
| &nbsp;&nbsp;&nbsp;&nbsp;Fixed asset impairment |  |  | 193 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustment for held-for-sale | (651) |  | 2868 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on disposal group | 4089 | 412 | 7327 | 624 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA (Non-GAAP measure) | $8483 | $17537 | $16776 | $32843 |
| Revenue | $86350 | $125190 | $173790 | $247801 |
| Adjusted EBITDA (Non-GAAP measure) | $8483 | $17537 | $16776 | $32843 |
| Adjusted EBITDA margin (Non-GAAP measure) | 9.8% | 14.0% | 9.7% | 13.3% |
| Revenue | $86350 | $125190 | $173790 | $247801 |
| Gross profit | $17153 | $48052 | $46438 | $90589 |
| Gross margin | 19.9% | 38.4% | 26.7% | 36.6% |

---

*Adjusted EBITDA*

The decrease in Adjusted EBITDA for the three and six months ended June 30, 2025, as compared to the prior year period, was primarily driven by declines in gross profit in the ongoing wholesale and retail operations and through restructuring and disposal activity, partially offset by improved leverage of revenues across selling, general, and administrative expenses such as facility costs, salary costs, and benefit costs.

Our future financial results are subject to significant potential fluctuations caused by, among other things, growth of sales volume in new and existing markets and our ability to control operating expenses. In addition, our financial results may be impacted significantly by changes to the regulatory environment in which we operate, on a local, state, and federal level.

**Liquidity and Capital Resources**

Our primary need for liquidity is to fund working capital requirements of our business, capital expenditures and for general corporate purposes. Historically, we have relied on external financing as our primary source of liquidity. Our ability to fund our operations and to make capital expenditures depends on our ability to successfully secure financing through issuance of debt or equity, as well as our ability to improve our future operating performance and cash flows, which are subject to prevailing economic conditions and financial, business and other factors, some of which are beyond our control.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

We are currently meeting our obligations and are earning revenues from our operations. However, we have sustained losses since inception and may require additional capital in the future. We estimate that based on our current business operations and working capital, we will continue to meet our obligations in the short term. As we continue to focus on profitability, we endeavor to remain opportunistic on growth through expansion or acquisition, therefore our cash flow requirements and obligations could materially change.

***Recent Financing Transactions***

*2026 Notes*

On February 3, 2022, the Company closed a private placement (the "February 2022 Private Placement") of $185,000 aggregate principal amount of 9.50% senior-secured first-lien notes due 2026 (the "2026 Notes") and received aggregate gross proceeds of $153,250. The 2026 Notes were senior secured obligations of the Company and were issued at 100.0% of face value. The 2026 Notes accrued interest in arrears which was payable semi-annually and were scheduled to mature on February 3, 2026, unless earlier redeemed or repurchased. The Company may redeem the 2026 Notes at par, in whole or in part, on or after February 3, 2024, as more particularly described in the fourth supplemental trust indenture governing the 2026 Notes. In connection with the offering of the 2026 Notes, the Company exchanged $31,750 of the Company's existing 13.0% senior secured first-lien notes (the "13.0% Term Debt"), pursuant to private agreements in accordance with the trust indenture, for an equivalent amount of 2026 Notes plus accrued but unpaid interest and any negotiated premium thereon.

The premium and paid interest were paid out of funds raised from the February 2022 Private Placement. The total unamortized debt premium and debt issuance costs of $2,153, related to the modified portion of the 13.0% Term Debt, was being amortized over the term of the 2026 Notes using the effective interest method. The Company incurred $7,189 in creditor fees in connection with the modified 13.0% Term Debt and 2026 Notes and $301 in third-party legal fees related to 2026 Notes, which were capitalized and were being amortized over the term of the 2026 Notes using the effective interest rate method.

On May 29, 2025, the 2026 Notes were exchanged for the 2028 Notes, see 2025 Debt Transactions (the 2028 Notes and the 2028 Convertible Notes). At the time of the exchange, the remaining unamortized debt premium, debt issuance costs, collector fees, and third party legal fees of $2,216 were written off.

*2027 Convertible Notes*

On March 19, 2024, the Company closed a private placement (the "March 2024 Private Placement") of $25,750 aggregate principal amount of 9.0% senior-secured first-lien notes due 2027 (the "2027 Notes") and received aggregate gross proceeds of $15,600. The 2027 Notes were senior secured obligations of the Company and were issued at 80.0% of face value. The 2027 Notes accrued interest in arrears which was payable semi-annually and were scheduled to mature on March 19, 2027. In connection with the offering of the 2027 Notes, the Company exchanged $5,000 of the Company's existing 6.0% 2025 Convertible Notes. Through June 30, 2025, 983,604 shares were issued to convert $300 principal.

The principal amount of the 2027 Convertible Notes and the conversion price were denominated in U.S. dollars. As the debt was issued out of the Company's Canadian Holding company, but the functional currency of the Company is US Dollars, the amount of the liability to be settled depends on the applicable foreign exchange rate on the date of settlement. The 2027 Convertible Notes therefore represented an obligation to issue a fixed number of shares for a variable amount of liability. Due to this conversion feature within the 2027 Convertible Notes, the Company was unable to obtain an exception from derivative accounting. Accordingly, this conversion feature was accounted for as an embedded derivative liability and measured at fair value of $2,632 on the date of issuance of debt with a corresponding debt discount and debt issuance costs of $5,952, reflected as a reduction to the carrying value of the 2027 Convertible Notes. The Company fair valued the derivative liability at each balance sheet date. Changes in fair value of the embedded derivative were recognized in the condensed consolidated interim statements of operations and comprehensive loss. The debt discount and debt issuance costs were being amortized over the term of the 2027 Convertible Notes.

On May 29, 2025, the 2027 Convertible Notes were exchanged for the 2028 Notes, see 2025 Debt Transactions (the 2028 Notes and the 2028 Convertible Notes). At the time of the exchange, the remaining unamortized debt discount and debt issuance costs of $3,759 were written off.

*2025 Convertible Notes*

On June 29, 2021, the Company completed an offering of 6.0% Secured Convertible Notes Due 2025 ("2025 Convertible Notes") for an aggregate principal amount of $74.5 million. The 2025 Convertible Notes were senior secured obligations of the Company and accrued interest payable semiannually in arrears and were scheduled to mature on June 29, 2025, unless earlier converted, redeemed, or repurchased.

The 2025 Convertible Notes shall be convertible, at the option of the holder, from the date of issuance until the date that is 10 days prior to their maturity date into Common Shares of the Company at a conversion price equal to $6.49 payable on the business day prior to the date of

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

conversion, adjusted downwards for any cash dividends paid to holders of Common Shares and other customary adjustments. The Company may redeem the 2025 Convertible Notes at par, in whole or in part, on or after June 29, 2023, if the volume weighted average price of the Common Shares trading on the Canadian Stock Exchange or Cboe Canada for 15 of the 30 trading days immediately preceding the day on which the Company exercises its redemption right, exceeds 120.0% of the conversion price of the 2025 Convertible Notes at a Redemption Price equal to 100.0% of the principal amount of the 2025 Convertible Notes redeemed, plus accrued but unpaid interest, if any, up to but excluding the Redemption Date.

The 2025 Convertible Notes required interest-only payments until June 29, 2025, at a rate of 6.0% per annum, payable semi-annually in June and December and commencing in December 2021. The 2025 Convertible Notes were scheduled to mature on June 29, 2025. The Company incurred financing costs of $3,190 in connection with the 2025 Convertible Notes. The principal amount of the 2025 Convertible Notes and the conversion price were denominated in U.S. dollars. As the debt was issued out of the Company's Canadian Holding company, but the functional currency of the Company is US Dollars, the amount of the liability to be settled depends on the applicable foreign exchange rate on the date of settlement. The 2025 Convertible Notes therefore represented an obligation to issue a fixed number of shares for a variable amount of liability. Due to this conversion feature within the 2025 Convertible Notes, the Company was unable to obtain an exception from derivative accounting. Accordingly, this conversion feature was accounted for as an embedded derivative liability and measured at fair value of $15,099 on the date of issuance of debt with a corresponding debt discount, reflected as a reduction to the carrying value of the 2025 Convertible Notes. The Company fair valued the derivative liability at each balance sheet date. Changes in fair value of the embedded derivative were recognized in the condensed consolidated interim statements of operations and comprehensive loss. The debt discount was amortized over the term of the 2025 Convertible Notes.

On May 29, 2025, the 2025 Convertible Notes were exchanged for the 2028 Notes, see 2025 Debt Transactions (the 2028 Notes and the 2028 Convertible Notes). At the time of the exchange, the remaining unamortized finance costs of $973, were written off.

*January 2024 Debt Exchange*

On January 22, 2024, the Company entered into an exchange agreement, as amended on June 30, 2024 and September 30, 2024 (the "Exchange Agreement"), with certain holders of the Company's 6.0% senior secured 2025 Convertible Notes (the "Holders"), pursuant to which the Company agreed to the repurchase of up to $25 million principal amount of the 2025 Convertible Notes in exchange for Common Shares (the "January 2024 Debt Exchange").

Pursuant to the terms of the Exchange Agreement, the Holders shall:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• by January 31, 2024, transfer $5 million principal amount of 2025 Convertible Notes in consideration of Common Shares issued at a price per Common Share equal to the greater of C$0.41 per Common Share and the 12.5% discount to the 5 days volume weighted average price of the Common Shares on Cboe prior to receipt of a Transfer notice;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• provided that the five-day volume weighted average price of the Common Shares on the Exchange is greater than C$0.47 as of the close of trading at 4:01pm on January 31, 2024, transfer $5 million principal amount of 2025 Convertible Notes in consideration of Common Shares issued at the Initial Exchange Price on or prior to February 29, 2024; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• provided that the February Exchange is completed and the daily volume weighted average price of the Common Shares on Cboe is greater than C$0.87 for 5 consecutive trading days, provided that, the trading volume of the Common Shares on Cboe was equal to or greater than 600,000 Common Shares on the applicable trading dates, from the period commencing on January 1, 2024 and ending on June 30, 2025, (which date the parties extended to December 31, 2024), transfer in three separate equal tranches, an aggregate of $15 million principal amount of 2025 Convertible Notes in consideration of Common Shares issued at a price per Common Share equal to the greater of C$0.57 per Common Share and the 12.5% discount to the 5 days volume weighted average price of the Common Shares on Cboe prior to receipt of a Transfer notice, in each case, subject to adjustment in certain instances, on or prior to December 31, 2024.

Through December 31, 2024, $10 million of the potential $25 million exchange had been completed. The term of the Exchange Agreement expired as of January 31, 2025.

*2025 Debt Transaction (the 2028 Notes and the 2028 Convertible Notes)* 

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

On February 27, 2025, the Company entered into a support agreement (the "Support Agreement") with certain holders (the "Supporting Noteholders") of the aggregate principal amount of issued Senior Notes (as defined below) regarding the exchange of their Senior Notes for new notes having a later maturity date and additional covenants (the "2025 Debt Transaction"). The Senior Notes consist of: (i) the 2025 Convertible Notes; (ii) the 2026 Notes; and (iii) the 2027 Convertible Notes (together with the 2025 Convertible Notes and the 2026 Notes, the "Senior Notes"). Under the terms of the 2025 Debt Transaction, among other provisions, the holders of the 2025 Convertible Notes and the 2026 Notes exchanged their Senior Notes for an equal principal amount of 9.25% Senior Secured Notes due December 31, 2028 (subject to two six-month extension options available to the Company upon payment of a 0.5% fee, payable in cash) (the new "2028 Notes") and the holders of the 2027 Convertible Notes received either (i) an equal principal amount of the 2028 Notes or (ii) if elected, an equal principal amount of newly issued 9.0% convertible notes, which have the same conversion price as the existing 2027 Convertible Notes but will the same extended maturity date as the 2028 Notes (the new "2028 Convertible Notes", and together with the 2028 Notes, the "New Notes").

The 2028 Notes and 2028 Convertible Notes require interest-only payments until December 31, 2028, payable semi-annually in June and December and commencing in December 2025 until maturity. The Company incurred financing costs of $12,155 in connection with the 2025 Debt Transaction. The principal amount of the 2028 Convertible Notes and the conversion price are denominated in U.S. dollars. As the debt was issued out of the Company's Canadian Holding company, but the functional currency of the Company is US Dollars, the amount of the liability to be settled depends on the applicable foreign exchange rate on the date of settlement. The 2028 Convertible Notes therefore represent an obligation to issue a fixed number of shares for a variable amount of liability. Due to this conversion feature within the 2028 Convertible Notes, the Company is unable to obtain an exception from derivative accounting. Accordingly, this conversion feature was accounted for as an embedded derivative liability and measured at fair value of $230 on the date of issuance of debt with a corresponding debt discount, reflected as a reduction to the carrying value of the 2028 Convertible Notes. The Company fair values the derivative liability at each balance sheet date. Changes in fair value of the embedded derivative are recognized in the condensed consolidated interim statements of operations and comprehensive loss. The debt financing costs are amortized over the term of the 2028 Notes and 2028 Convertible Notes.

In addition, as part of the 2025 Debt Transaction, the Company issued 118,209,105 warrants to the Company shareholders on a pro rata basis, see Note 10 Warrants.

The 2028 Notes and 2028 Convertible Notes are secured by a first-priority security interest in all present and after-acquired personal property of the Company, including a pledge of the Equity Interests owned by the Issuer and each Guarantor; and a collateral assignment of leases in respect of certain leasehold property and all of the Company's interests therein as defined in the Amended and Restated Trust Indenture.

The Company completed its 2025 Debt Transaction effective May 29, 2025 following receipt of court approval.

*Mortgages*

In December 2021, the Company entered into a term loan and security agreement with a bank. The agreement provides for a $20,000 mortgage on real property in New York and carries interest at a variable rate per annum equal to the Wall Street Prime Rate ("Index") plus 2.25%. The debt is repayable in 59 monthly installments and a final balloon payment due on January 1, 2027, which is estimated at $17,920 as of June 30, 2025. In connection with this mortgage, the Company incurred financing costs of $655.

In June 2022, the Company entered into a term loan and security agreement with a bank. The agreement provides for a $16,500 mortgage on real property in New Jersey and carries interest at a variable rate per annum equal to the Index plus 2.25%. The debt is repayable in 59 monthly installments and a final balloon payment due on July 15, 2027, which is estimated at $15,549 as of June 30, 2025. In connection with this mortgage, the Company incurred financing costs of $209.

On August 10, 2023, the Company entered into two term loans and security agreements with a bank as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The first agreement provides for a $6,250 mortgage on real property in Maryland and carries interest at a variable rate per annum equal to the Index plus 2.25%. The debt is repayable in 59 monthly installments and matures in August 2028. In connection with this mortgage, the Company incurred financing costs of $195 and netted $2,903 after the repayment of a prior outstanding mortgage on the property.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The second agreement provides for a $1,800 mortgage on real property in Delaware and carries interest at a variable rate per annum equal to the Index plus 2.25%. The debt is repayable in 59 monthly installments and matures in August 2028. In connection with this mortgage, the Company incurred financing costs of $77 and netted $1,723. The mortgage was paid in full on January 15, 2025 with the sale of the property.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

The weighted average interest rate on the Company's indebtedness was 9.23%.

***Cash Flows***

The following table summarizes the sources and uses of cash for each of the periods presented:

---

| | | |
|:---|:---|:---|
| | **Six months ended** | **Six months ended** |
| | **June 30, 2025** | **June 30, 2024** |
| Net cash used in operating activities | $(11072) | $(9659) |
| Net cash provided by investing activities | 5939 | 856 |
| Net cash used in financing activities | (14206) | $(4629) |
| Net decrease in cash | $(19339) | $(13432) |

---

*Operating Activities*

During the six months ended June 30, 2025, operating activities used $11,072 of cash, primarily resulting from a net loss of $109,592 and this was partly offset by deferred income tax of $31,694, depreciation and amortization of $16,851, debt amortization expenses of $10,678, loss on deconsolidation of subsidiary of $10,494, change in investment fair value of $6,520, loss on early extinguishment of note of $3,227, provision for credit losses of $2,238, provision for obsolete inventory and other assets of $10,752, equity based compensation of $935, change in fair value of derivative liability of $359, impairment of fixed assets of $193, other expenses of $106, and net change in operating assets and liabilities of $13,953. The net change in operating assets and liabilities was primarily due to a decrease in notes receivable of $19,350, a decrease in inventory of $4,656, a decrease in other assets of $4,082; this was partially offset by a decrease in accrued expenses and other current liabilities of $12,616, a decrease in accounts payable of $9,108, an increase in income tax payable of $273, an increase in other long-term liabilities of $1,521, an increase in accounts receivable of $840, and an increase prepaid expenses and other current assets of $2,665.

During the six months ended June 30, 2024, operating activities used $9,659 of cash, primarily resulting from a net loss of $48,211, deferred taxes of $1,080, other items of $343, and equity-based compensation expense of $4,962, legal settlement of $1,108; this was partially offset by depreciation and amortization of $27,547, debt amortization expense of $4,307, provision for credit losses of $964, provision for obsolete inventory of $5,642, loss on deconsolidation of subsidiary of $624, change in fair value of derivative liability of $2,329, and net change in operating assets and liabilities of $5,596. The net change in operating assets and liabilities was primarily due to a decrease in other assets of $728, an increase in accounts payable of $4,138, an increase in income tax payable of $17,367, an increase in accrued expenses and other current liabilities of $12, and an increase in other long term liabilities of $609. This was offset by an increase in accounts receivable of $4,868, an increase in prepaid expenses and other current assets of $3,214, and an increase in inventory of $10,140.

*Investing Activities* 

During the six months ended June 30, 2025, investing activities provided $5,939 of cash, mainly due to the proceeds from the sale of business of $5,687, proceeds from the sale of license of $4,000, and cash received on deposits, net of $108. This was partially offset by purchases of property and equipment of $3,856.

During the six months ended June 30, 2024, investing activities provided $856 of cash mainly due to the proceeds from the sale of the UT business of $2,999, cash received on deposits, net of $157, and proceeds from sale of license of $329. This was partially offset by purchases of property and equipment of $2,629.

*Financing Activities* 

During the six months ended June 30, 2025, financing activities used $14,206 of cash, mainly due to payment of debt issuance costs of $12,155, payment of lease liabilities of $1,466, repayment of notes payable of $100, repayment of mortgage notes of $353, taxes paid on equity based compensation of $120, and distributions of $12.

During the six months ended June 30, 2024, financing activities used $4,629 of cash, mainly due to repayments of debt of $13,228, payment of lease liabilities of $3,582, payment of debt issuance costs of $802, repayment of sellers note of $750, taxes paid on equity based compensation of $1,255, distributions of $333, and repayment of mortgage notes of $279. This was partially offset by proceeds from issuance of convertible debt of $15,600.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

**Contractual Obligations and Commitments**

The following table summarizes contractual obligations as of June 30, 2025 and the effects that such obligations are expected to have on our liquidity and cash flows in future periods:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Payments Due by Period** | **Payments Due by Period** | **Payments Due by Period** | **Payments Due by Period** | **Payments Due by Period** | **Payments Due by Period** | **Payments Due by Period** |
| | **Total** | **Less than 1 year** | **Year 1** | **Year 2** | **Year 3** | **Year 4** | **Year 5 and beyond** |
| Lease commitments | $223732 | $11620 | $22471 | $21992 | $19887 | $17386 | $130376 |
| Sale-leaseback commitments | 206068 | 5258 | 10743 | 11090 | 11449 | 11819 | 155709 |
| 2028 Notes (principal) | 250750 |  |  |  | 250750 |  |  |
| Interest on 2028 notes | 83373 | 13790 | 23194 | 23131 | 23258 |  |  |
| 2028 Convertible notes (principal) | 19200 |  |  |  | 19200 |  |  |
| Interest on convertible debt | 6211 | 1027 | 1728 | 1723 | 1733 |  |  |
| Mortgage notes (principal) | 40789 | 362 | 793 | 33675 | 5959 |  |  |
| Mortgage notes (interest) | 9315 | 3112 | 4065 | 1684 | 454 |  |  |
| Total contractual obligations | 839438 | 35169 | 62994 | 93295 | 332690 | 29205 | 286085 |

---

The above table excludes purchase orders for inventory in the normal course of business.

**Effects of Inflation** 

Rising inflation rates have had a substantial impact on our financial performance to date and may have an impact on our financial performance in the future as our ability to pass on an increase in costs is not entirely within our control.

**Critical Accounting Estimates**

We make judgements, estimates and assumptions about the future that affect assets and liabilities, and revenues and expenses. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the review affects both current and future periods.

Judgements, estimates, and assumptions with the most significant effect on the amounts recognized in the consolidated financial statements are described below.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

**FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT** 

Our financial instruments consist of cash and cash equivalents, accounts receivable, notes receivable, deposits and other current assets, accounts payable, accrued expenses, current taxes payable and other current liabilities like interest payable and payroll liabilities, derivative liability, debt, and lease liabilities. The fair values of cash and restricted cash, accounts and notes receivable, deposits, accounts payable and accrued expenses and other current liabilities like interest payable and payroll liabilities, short-term debt and lease liabilities approximate their carrying values due to the relatively short-term to maturity or because of the market rate of interest used on initial recognition. The Cannabist Company classifies its derivative liability as fair value through profit and loss (FVTPL).

Financial instruments recorded at fair value are classified using a fair value hierarchy that reflects the significance of the inputs to fair value measurements. The three levels of fair value contained within the hierarchy are:

Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities;

Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly; and

Level 3 – Inputs for the asset or liability that are not based on observable market data.

Our assets measured at fair value on a nonrecurring basis include investments, assets and liabilities held for sale, long-lived assets, and indefinite-lived intangible assets. We review the carrying amounts of such assets whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable or at least annually, for indefinite-lived intangible assets. Any resulting asset impairment would require that the asset be recorded at its fair value. The resulting fair value measurements of the assets are considered Level 3 measurements.

**Financial Risk Management**

We are exposed, in varying degrees, to a variety of financial instrument related risks. Our risk exposures and the impact on our financial instruments is summarized below:

*Credit Risk*

Credit risk is the risk of a potential loss to us if a customer or third party to a financial instrument fails to meet its contractual obligations. The maximum credit exposure at June 30, 2025 and December 31, 2024, is the carrying amount of cash and cash equivalents, subscription receivable, accounts receivable and notes receivable. We do not have significant credit risk with respect to our customers. All cash deposits are with regulated U.S. financial institutions.

We provide credit to our customers in the normal course of business and have established credit evaluation and monitoring processes to mitigate credit risk but have limited risk as the majority of our sales are transacted with cash.

*Liquidity Risk*

Liquidity risk is the risk that we will not be able to meet our financial obligations associated with financial liabilities. We manage liquidity risk through the management of our capital structure. Our approach to managing liquidity is to estimate cash requirements from operations, capital expenditures and investments and ensure that we have sufficient liquidity to fund our ongoing operations and to settle obligations and liabilities when due.

To date, we have incurred significant cumulative net losses and we have not generated positive cash flows from our operations. We have therefore depended on financing from the sale of our equity and from debt financing to fund our operations. Overall, we do not expect the net cash contribution from our operations and investments to be positive in the near term, and we therefore expect to rely on financing from equity or debt.

*Market Risk*

In addition to business opportunities and challenges applicable to any business operating in a fast-growing environment, our business operates in a highly regulated and multi-jurisdictional industry, which is subject to potentially significant changes outside of our control as individual states as well as the U.S. federal government may impose restrictions on our ability to grow our business profitably or enact new laws and regulations that open up new markets.

*Interest Rate Risk*

Interest rate risk is the risk that the fair value or future cash flows of our financial instrument will fluctuate because of changes in market interest rates. Our cash deposits bear interest at market rates.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

*Currency Risk*

Our operating results and financial position are reported in thousands of U.S. dollars. We may enter into financial transactions denominated in other currencies, which would result in your operations and financial position becoming subject to currency transaction and translation risks.

As of June 30, 2025, and December 31, 2024, we had no hedging agreements in place with respect to foreign exchange rates. We have not entered into any agreements or purchased any instruments to hedge possible currency risks at this time.

*Price Risk*

Price risk is the risk of variability in fair value due to movements in equity or market prices. We are subject to the risk of price variability pursuant to our products due to competitive or regulatory pressures.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

There have been no significant material changes to the market risks as disclosed in the Company's 2024 Form 10-K. See also Financial Risk Management in Part I, Item 2 of this Form 10-Q.

**Item 4. Controls and Procedures.**

*Disclosure Controls and Procedures*

The Company's management, with the participation of the Company's Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company's disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report were effective to provide reasonable assurance that the information required to be disclosed by the Company in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms and that it is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

*Changes in Internal Control*

There were no changes in the Company's internal control over financial reporting (as defined in Rules 13a-15(f) under the Securities Exchange Act of 1934, as amended) during the three months ended June 30, 2025 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

**PART II—OTHER INFORMATION** 

**Item 1. Legal Proceedings.**

Murchinson Ltd., an investment manager of holders of 2025 Convertible Notes and 2027 Convertible Notes (the "Applicant"), filed an application in the Ontario Superior Court of Justice (Commercial List) (the "Court") on March 27, 2025, opposing the 2025 Debt Transaction and claiming the transaction was oppressive to the Applicant. The application filed by the Applicant also claims breach of contract and civil conspiracy. The Applicant seeks from the court, among other forms of relief, that the 2025 Debt Transaction be declared unlawful under the terms of the Canadian Business Corporations Act, an award of unspecified damages, and recovery of costs. By order dated May 21, 2025, the Court ruled in favor of the Company and the 2025 Debt Transaction was subsequently closed. Murchinson Ltd. has filed appeals to the Court of Appeal for Toronto that are currently pending.

**Item 1A. Risk Factors**

As of the date of this filing, there have been no material changes in our risk factors from those disclosed in Part I, Item 1A, of the Company's 2024 Form 10-K, which is incorporated by reference herein.

*The Company may not be able to retain or hire necessary qualified personnel*

The Company's ability to retain or hire qualified personnel is subject to a variety of uncertainties due to the challenging

financial conditions facing both the industry and the Company. If the Company is unable to retain or hire sufficiently

qualified resources, the Company may have difficulty executing on its operational and strategic plans.

**Item 2. Unregistered Sales of Securities and Use of Proceeds**

None.

**Item 3. Defaults Upon Senior Securities.**

Not applicable.

**Item 4. Mine Safety Disclosures.**

Not applicable.

**Item 5. Other Information.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)Not applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Securities Trading Plans of Directors and Executive Officers

During the three months ended June 30, 2025, none of our directors or executive officers adopted or terminated any contract, instruction, or written plan for the purchase or sale of the Company's securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any "non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K.

**Item 6. Exhibit Index**

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description** |
| 2.1 | <u>[Arrangement Agreement, dated March 23, 2022, between Cresco Labs Inc. and Columbia Care Inc. (incorporated by reference to Exhibit 2.1 of the Registrant's Current Report on Form 8-K, filed with the SEC on March 29, 2022)](https://www.sec.gov/Archives/edgar/data/1776738/000119312522088069/d292116dex21.htm)</u> |
| 2.2 | <u>[Amending Agreement, dated February 27, 2023, between Cresco Labs Inc. and Columbia Care Inc. (incorporated by reference to Exhibit 2.1 of the Registrant's Current Report on Form 8-K, filed with the SEC on February 28, 2023)](https://www.sec.gov/Archives/edgar/data/1776738/000119312523054004/d469358dex21.htm)</u> |
| 3.1 | <u>[Articles, dated April 26, 2019 (incorporated by reference to Exhibit 3.1 of the Registrant's Form 8-K, filed with the SEC on September 22, 2023)](https://www.sec.gov/Archives/edgar/data/1776738/000119312521356939/d252333dex31.htm)</u> |
| 3.2 | <u>[Certificate of Change of Name, dated September 19, 2023 (incorporated by reference to Exhibit 3.2 of the Registrant's Form 8-K, filed with the SEC on September 22, 2023)](https://www.sec.gov/Archives/edgar/data/1776738/000119312523239776/d471022dex32.htm)</u> |

---

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

---

| | |
|:---|:---|
| 4.1 | <u>[Warrant Agency Agreement dated September 20, 2018 between Canaccord Genuity Growth Corp. and Odyssey Trust Company (incorporated by reference to Exhibit 4.1 of the Registrant's Registration Statement on Form 10, filed with the SEC on December 14, 2021)](https://www.sec.gov/Archives/edgar/data/1776738/000119312521356939/d252333dex41.htm)</u> |
| 4.2 | <u>[Warrant Agreement dated April 26, 2019 between Columbia Care Inc. and Canaccord Genuity Corp. (incorporated by reference to Exhibit 4.2 of the Registrant's Registration Statement on Form 10, filed with the SEC on December 14, 2021)](https://www.sec.gov/Archives/edgar/data/1776738/000119312521356939/d252333dex42.htm)</u> |
| 4.3 | <u>[Trust Indenture made as of March 31, 2020 between Columbia Care Inc. and Odyssey Trust Company (incorporated by reference to Exhibit 4.3 of the Registrant's Registration Statement on Form 10, filed with the SEC on December 14, 2021)](https://www.sec.gov/Archives/edgar/data/1776738/000119312521356939/d252333dex43.htm)</u> |
| 4.4 | <u>[Warrant Indenture dated March 31, 2020 between Columbia Care Inc. and Odyssey Trust Company (incorporated by reference to Exhibit 4.4 of the Registrant's Registration Statement on Form 10, filed with the SEC on December 14, 2021)](https://www.sec.gov/Archives/edgar/data/1776738/000119312521356939/d252333dex44.htm)</u> |
| 4.5 | <u>[Warrant Indenture dated May 14, 2020 between Columbia Care Inc. and Odyssey Trust Company (incorporated by reference to Exhibit 4.6 of the Registrant's Registration Statement on Form 10, filed with the SEC on December 14, 2021)](https://www.sec.gov/Archives/edgar/data/1776738/000119312521356939/d252333dex46.htm)</u> |
| 4.6 | <u>[Warrant Indenture dated July 2, 2020 between Columbia Care Inc. and Odyssey Trust Company (incorporated by reference to Exhibit 4.8 of the Registrant's Registration Statement on Form 10, filed with the SEC on December 14, 2021)](https://www.sec.gov/Archives/edgar/data/1776738/000119312521356939/d252333dex48.htm)</u> |
| 4.7 | <u>[Warrant Indenture dated October 29, 2020 between Columbia Care Inc. and Odyssey Trust Company (incorporated by reference to Exhibit 4.9 of the Registrant's Registration Statement on Form 10, filed with the SEC on December 14, 2021)](https://www.sec.gov/Archives/edgar/data/1776738/000119312521356939/d252333dex49.htm)</u> |
| 4.8 | <u>[Extension Notice dated March 28, 2023 to Odyssey Trust Company (incorporated by reference to Exhibit 4.14 of the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on March 29, 2023)](https://www.sec.gov/Archives/edgar/data/1776738/000095017023010606/cchwf-ex4_14.htm)</u> |
| 4.9 | <u>[Amended and Restated Trust Indenture, among The Cannabist Company Holdings Inc. and The Cannabist Company Holdings (Canada) Inc, as co-issuers, and Odyssey Trust Company, as Trustee, dated May 29, 2025 (incorporated by reference to Exhibit 4.1 of the Registrant's Current Report on Form 8-K, filed with the SEC on June 4, 2025)](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001776738/000110465925056402/tm2517085d1_8k.htm)</u> |
| 4.10 | <u>[First Supplemental Indenture, among The Cannabist Company Holdings Inc. and The Cannabist Company Holdings (Canada) Inc, as co-issuers, and Odyssey Trust Company, dated May 29, 2025 (incorporated by reference to Exhibit 4.2 of the Registrant's Current Report on Form 8-K, filed with the SEC on June 4, 2025)](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001776738/000110465925056402/tm2517085d1_8k.htm)</u> |
| 10.1\*† | <u>[Amendment to the Promissory Note effective May 27, 2025 between Verano Holdings, LLC and The Cannabist Company Holdings Inc](cbstf-20250630exhibit101.htm)</u>. |
| 10.2\* | <u>[Waiver and Partial Payoff Agreement dated May 27, 2025 between Verano Holdings, LLC, The Cannabist Company Holdings Inc., and CC VA Holdco LLC.](cbstf-20250630exhibit102.htm)</u> |
| 10.3 | <u>[Warrant Agency Agreement, between The Cannabist Company Holdings Inc. and Odyssey Trust Company, as Warrant Agent, dated May 29, 2025 (incorporated by reference to Exhibit 10.1 of the Registrant's Current Report on Form 8-K, filed with the SEC on June 4, 2025)](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001776738/000110465925056402/tm2517085d1_8k.htm)</u> |
| 10.4\*# | <u>[Summary of The Cannabist Company Holdings Inc. Transaction Bonus Plan](cbstf-20250630exhibit104.htm)</u> |
| 10.5\*# | <u>[Second Amended and Restated At-Will Employment Agreement dated July 17, 2025 between The Cannabist Company Holdings Inc. and Jesse Channon](cbstf-20250630exhibit105.htm)</u> |
| 31.1\* | <u>[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](cnstf-20250630xexx311.htm)</u> |
| 31.2\* | <u>[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](cnstf-20250630xexx312.htm)</u> |
| 32.1‡ | <u>[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](cnstf-20250630xexx321.htm)</u> |
| 32.2‡ | <u>[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](cnstf-20250630xexx322.htm)</u> |
| 101.INS\* | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH\* | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL\* | Inline XBRL Taxonomy Extension Calculation Linkbase Document |

---

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

---

| | |
|:---|:---|
| 101.DEF\* | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB\* | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE\* | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104\* | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

________________________

\*Filed herewith.

#† Certain identified information has been omitted pursuant to Item 601(b)(10) of Regulation S-K because such information is both (i) not material and (ii) of the type that the Registrant customarily and actually treats as private or confidential. The Registrant hereby undertakes to furnish supplemental copies of the unredacted exhibit upon request by the SEC.

‡Document has been furnished, is not deemed filed and is not to be incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, irrespective of any general incorporation language contained in any such filing.

------

<u>[**Table of Contents**](#if4efeb26950b44de969aebf0b8cd78b7_7)</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **THE CANNABIST COMPANY HOLDINGS INC.** | **THE CANNABIST COMPANY HOLDINGS INC.** |
| Date: August 7, 2025 | By: | /s/ David Hart |
|  |  | **David Hart** |
|  |  | **Chief Executive Officer** |
| Date: August 7, 2025 | By: | /s/ Derek Watson |
|  |  | **Derek Watson** |
|  |  | **Chief Financial Officer** |

---

## Exhibit 10.1

Certain information marked with "[\*\*\*]" has been excluded from the exhibit because it is both not material and is the type that the Registrant treats as private and confidential.

**<u>AMENDMENT TO THE</u>**

**<u>PROMISSORY NOTE</u>**

THIS AMENDMENT TO THE PROMISSORY NOTE (this "<u>Amendment</u>") is effective as of May 27, 2025, by and between Verano Holdings, LLC, a Delaware limited liability company ("<u>Buyer</u>"), and The Cannabist Company Holdings Inc., a British Columbia corporation, acting in its individual capacity and as the Member representative ("<u>Cannabist</u>").

<u>RECITALS</u>

**WHEREAS**, Buyer issued a promissory note, dated August 21, 2024 (the "<u>Promissory Note</u>"), in the principal amount of $26,700,000 (the "<u>Principal</u>") and in favor of the members (collectively, the "<u>Members</u>") of Columbia Care Eastern Virginia LLC, a Virginia limited liability company (the "<u>Company</u>");

**WHEREAS**, pursuant to (a) Section 2.4(c) of that certain equity purchase agreement, dated as of July 29, 2024, by and among Buyer, Verano Holdings Corp., a British Columbia corporation, the Company, the Members and Cannabist (the "<u>EPA</u>"), and (b) Section 7 of the Promissory Note, the parties thereto agreed that the Promissory Note shall be amended to increase the Principal amount by the Excess Amount (as defined in the EPA) calculated in accordance with the EPA;

**WHEREAS**, pursuant to Section 6.2(e) of the EPA, any indemnification payments to be made by Cannabist may be made by deducting such amount from the amount due to the Members, on a several basis, under the Promissory Note;

**WHEREAS**, the parties hereto agreed that Cannabist and the Members were obligated to indemnify Buyer for $39,179 (the "[\*\*\*] Amount") in connection with [\*\*\*];

**WHEREAS**, in accordance with the EPA, Buyer and Cannabist agreed that the Excess Amount equals $1,190,813, and accordingly, Buyer and Cannabist agree that the Promissory Note shall be amended to increase the Principal by $1,151,634 (which amount equals the Excess Amount *minus* the [\*\*\*] Amount) to $27,851,634;

**WHEREAS**, the Promissory Note may be amended by the written agreement of Buyer and Cannabist; and

**WHEREAS**, the parties hereto desire to amend the Promissory Note as set forth herein, in accordance with the terms set forth in the Promissory Note.

&nbsp;&nbsp;&nbsp;&nbsp;**NOW, THEREFORE**, in consideration of the premises, the mutual covenants set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:

<u>AGREEMENT</u>

131405909.1 ------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.<u>Definitions</u>. Capitalized terms used herein and not defined herein shall have the meaning ascribed to such term as set forth in the Promissory Note, and all references to Sections shall mean the Sections of the Promissory Note unless reference is made to another document.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.<u>Amendments to the Promissory Note</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All references to $26,700,000 in the Promissory Note are hereby amended and replaced in their entirety to "*$27,851,634*".

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)A new sentence shall be added to the end of Section 2(b) of the Promissory Note reading as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)*Notwithstanding anything contained herein to the contrary, to the extent all principal and accrued Interest has been repaid in full prior to the Maturity Date, Buyer shall have no further payments or obligations due to the Members, and the Members shall have no further right or title to any payments, under this Promissory Note.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.<u>Full Force and Effect</u>. Except as specifically amended, modified, or supplemented by this Amendment, the Promissory Note, as amended, shall remain unchanged and in full force and effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.<u>Governing Law</u>. The parties hereto expressly agree that this Amendment shall be governed by, and construed in accordance with, the laws of the State of Delaware.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.<u>Counterparts</u>. This Amendment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature) or other commonly recognized transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

6.[Signature Page Follows]

&nbsp;&nbsp;&nbsp;&nbsp;2

4860-5770-6488, v. 2

------

**IN WITNESS WHEREOF**, the parties have executed this Amendment as of the date first written.

**BUYER:**

Verano Holdings, LLC

By<u>&nbsp;&nbsp;&nbsp;&nbsp;/s/ George P. Archos&nbsp;&nbsp;&nbsp;&nbsp;</u>

Name: George P. Archos

Title: Chief Executive Officer

**CANNABIST:**

The Cannabist Company Holdings Inc.

By<u>&nbsp;&nbsp;&nbsp;&nbsp;/s/ David Hart&nbsp;&nbsp;&nbsp;&nbsp;</u>

Name: David Hart

Title: Chief Executive Officer

131405909.1

## Exhibit 10.2

**WAIVER AND PARTIAL PAYOFF AGREEMENT**

&nbsp;&nbsp;&nbsp;&nbsp;THIS WAIVER AND PARTIAL PAYOFF AGREEMENT (this "<u>Agreement</u>") is entered into as of May 27, 2025, by and among Verano Holdings, LLC ("<u>Buyer</u>"), The Cannabist Company Holdings Inc., a British Columbia corporation ("<u>Cannabist</u>"), and CC VA Holdco LLC, a Delaware limited liability company ("<u>CC VA</u>"). Buyer, Cannabist and CC VA are referred to in this Agreement, individually, as a "<u>Party</u>" and collectively, as the "<u>Parties</u>".

**RECITALS**

&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Parties are party, among others, to that certain Promissory Note, dated as of August 21, 2024 in the original principal amount of $26,700,000 (as amended or otherwise modified from time to time, the "<u>Promissory Note</u>"), pursuant to which Buyer, as the borrower thereunder, is obligated to pay such principal amount, accrued interest thereon, and other amounts as set forth therein, to CC VA and the other Members party thereto (unless otherwise defined herein, each capitalized term used herein has the meaning assigned thereto in the Promissory Note);&nbsp;&nbsp;&nbsp;&nbsp;

WHEREAS, Buyer may at any time voluntarily prepay in cash the principal outstanding under the Promissory Note in whole or in part, together with accrued and unpaid interest on the portion of principal so prepaid;

WHEREAS, any prepayment made by Buyer must be paid to each of the Members in accordance with their respective Pro Rata Shares (the "<u>Pro Rata Payment Requirement</u>");

WHEREAS, any provision of the Promissory Note may be amended, waived or modified upon the written consent of Buyer and Cannabist;

WHEREAS, Buyer and Cannabist wish to modify the Promissory Note to waive the Pro Rata Payment Requirement with respect to the prepayment contemplated by this Agreement;

WHEREAS, as of May 27, 2025, the portion of the principal amount of the Promissory Note, accrued and unpaid interest thereon and all other amounts thereunder owing to CC VA is $13,931,001 (the "<u>CC VA Note Balance</u>");

&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, that Parties have agreed that it is in their mutual best interest for Buyer to voluntarily prepay the CC VA Note Balance to CC VA in full on the date hereof in exchange for a 25% discount, which discounted CC VA Note Balance is $10,448,250.75;

&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Parties desire for the CC VA Note Balance to be further reduced by (a) $94,582 pursuant to that certain Final Purchase Price Confirmation Agreement (the "<u>SWC True-Up</u>"), dated as of the date hereof, by and between Verano Arizona, LLC, an Arizona limited liability company ("<u>Verano AZ</u>), and Cannabist, (b) $351,300 pursuant to that certain Final Purchase Price Confirmation Agreement (the "<u>203 True-Up</u>"), dated as of the date hereof, by and between Verano AZ and Cannabist and (c) $700,000, which amount reflects a partial payment of wholesale payables due from Cannabist and its Affiliates to Buyer and its Affiliates (the "<u>Wholesale Partial Payment</u>"); and

------

&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, in full satisfaction of Buyer's obligations to CC VA under the Promissory Note, Buyer has agreed to make a payment of $9,302,368.75 (the "<u>Payoff Amount</u>") to CC VA on May 27, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the foregoing and the respective covenants and agreements set forth herein, and intending to be legally bound, subject to the conditions and other terms herein set forth, the Parties hereby agree as follows:

**AGREEMENTS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.The Promissory Note is hereby modified to waive the Pro Rata Payment Requirement with respect to the prepayment made by Buyer to CC VA in accordance with this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Buyer shall pay the Payoff Amount by wire transfer of immediately available funds to CC VA on May 27, 2025 in full satisfaction of (a) Buyer's obligations to CC VA under the Promissory Note, (b) Cannabist's obligations to Buyer and Verano AZ under the SWC True-Up and 203 True-Up, and (c) Cannabist's and its Affiliates' obligations to Buyer and its Affiliates for the Wholesale Partial Payment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Upon receipt by CC VA of the Payoff Amount, all obligations of Buyer to CC VA under the Promissory Note, including principal, accrued interest, expenses and fees, shall be paid in full and any obligations of Buyer under the Promissory Note owing to CC VA and rights of CC VA thereunder shall be automatically terminated and released in full.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.Upon receipt by CC VA of the Payoff Amount, (a) all obligations of Cannabist and CC VA owing to Buyer and Verano AZ for the SWC True-Up and the 203 True-Up, and (b) all obligations of Cannabist and its Affiliates owing to Buyer and its Affiliates for the amount of the Wholesale Partial Payment, automatically shall be deemed paid in full and cancelled, and any obligations of Cannabist, CC Va and their Affiliates thereunder owing to Buyer and its Affiliates shall be automatically terminated and released in full.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.After payment of the Payoff Amount, CC VA and Cannabist shall execute and deliver to Buyer (or its designee), from time to time, all lien releases, termination statements, certificates, instruments, and documents reasonably requested by Buyer to evidence the payment in full of obligations of Buyer owing to CC VA under the Promissory Note, each in form and substance reasonably satisfactory to Buyer, and take (and hereby authorizes Buyer or any of its authorized designees to take) any other actions, as may be reasonably requested by Buyer to evidence the consummation of the payment in full of the CC VA Note Balance contemplated hereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.Buyer acknowledges and agrees that (a) its obligations and liabilities under the Promissory Note owing to the other Members remain in full force and effect and have not been modified or reduced pursuant to this Agreement, except as it relates to the waiver of the Pro Rata

------

Payment Requirement contemplated hereby and (b) its obligations and liabilities owing to CC VA under the Promissory Note shall be reinstated with full force and effect if, at any time on or after the date hereof, all or any portion of the Payoff Amount paid to CC VA is voided or rescinded or must otherwise be returned to Buyer or any other person upon the insolvency, bankruptcy or reorganization of Buyer or otherwise, all as though such payment had not been made.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.This Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.This Agreement shall be governed by, and construed in accordance with the law of the State of Delaware applicable to contracts to be carried out wholly within such State.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.This Agreement may be executed simultaneously in multiple counterparts, and in separate counterparts, each of which shall be deemed an original, but both of which taken together shall constitute one and the same instrument.

*[Signature page follows]*

&nbsp;&nbsp;&nbsp;&nbsp;

------

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed and delivered as of the date first written above.

BUYER:

**VERANO HOLDINGS, LLC**

By: <u>__/s/ George Archos</u>__<br>Name: George Archos<br>Title: CEO

&nbsp;&nbsp;&nbsp;&nbsp;

CANNABIST:

**THE CANNABIST COMPANY HOLDINGS INC.**

By: _<u>/s/ David Hart __________</u><br>Name: David Hart <br>Title: CEO

CC VA:

**CC VA HOLDCO LLC**

By: __<u>/s/ David Hart __________</u><br>Name: David Hart<br>Title: President

## Exhibit 10.4

**Summary of The Cannabist Company Holdings Inc. Transaction Bonus Plan**

On July 16, 2025 (the "Effective Date"), the Compensation Committee of the Board of Directors (the "Board") of The Cannabist Company Holdings Inc. (the "Company") approved a Transaction Bonus Plan (the "Bonus Plan"). Under the Bonus Plan, the Company will establish a bonus pool (the "Bonus Pool"). The size of the Bonus Pool will be 1.50% of the transaction value, as defined and determined by the Compensation Committee, for divestitures or other strategic transactions, not previously approved by the Board, that are closed while the Bonus Plan is in effect. The Bonus Pool, if qualifying divestitures or strategic transactions are completed, will be funded directly from funds available for general corporate purposes and will be capped at $5,000,000. Certain key employees of the Company who are designated as participants will be eligible to be paid a bonus or bonuses based on individual allocations of the Bonus Pool, as determined by the Compensation Committee. Payments will be made to participants as follows: one-third of the individual's Bonus Pool allocation payable as soon as practicable following each transaction close, one-third of the individual's Bonus Pool allocation payable 60 days post-close and one-third of the individual's Bonus Pool allocation payable 90 days post-close.

Unpaid bonuses will be forfeited upon voluntary termination or termination for cause of an eligible employee following the closing of a qualifying transaction. In the event of involuntary termination without cause following the closing of a qualifying transaction, the eligible employee will receive any unpaid bonuses, subject to the execution of a standard release agreement. In the event of involuntary termination without cause prior to the closing of a qualifying transaction, the eligible employee will be ineligible for a bonus with respect to any transaction that has not yet closed as of the termination date.

The term of the Bonus Plan commences on the Effective Date and shall continue until otherwise determined by the Compensation Committee of the Board.

4925-8981-4875\1

## Exhibit 10.5

**<u>SECOND AMENDED AND RESTATED AT-WILL EMPLOYMENT AGREEMENT</u>**

**THIS SECOND AMENDED AND RESTATED AT-WILL EMPLOYMENT AGREEMENT** (the "Agreement"), is made and entered into as of the 17<sup>th</sup> day of July, 2025 (the "Effective Date"), between The Cannabist Company Holdings Inc. (f/k/a Columbia Care Inc.), a British Columbia corporation with a principal place of business at 680 Fifth Avenue, New York, NY 10019 (which hereinafter includes any successor, parent, subsidiary and affiliate, and is collectively referred to as the "Company"), and Jesse Channon, an individual (hereinafter referred to as "Employee" or ''you"). The Employee and the Company previously entered into an At-Will Employment Agreement, as amended (the "Original Agreement"), dated November 26, 2019 (the "Original Effective Date") and an Amended and Restated At-Will Employment Agreement, dated March 11, 2024. The Employee and the Company now desire to amend and restate the Original Agreement and the Amended and Restated At-Will Employment Agreement on the terms and conditions set forth herein. In consideration of the promises and the mutual covenants herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto mutually agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;1.**<u>Eligibility For Employment.</u>** The Immigration Reform and Control Act requires all employees of U.S. companies to have evidence of identity and authorization to work in the U.S. Employee represents and warrants that Employee has such authorization and will provide the Company with evidence thereof on or before the Effective Date of this Agreement. Employee further acknowledges that the Company may perform a background check on Employee.

2.**<u>At-Will Employment.</u>** Employee's employment hereunder shall be at-will and can be terminated at any time, for any or no reason, and with or without cause. Employee's employment pursuant to this Agreement will be effective on July 17, 2025 and shall continue until terminated by either party hereunder. The period of time during which Employee is employed as an at-will employee shall be referred to herein as the "Employment Period." The date on which Employee's employment terminates shall be referred to herein as the "Termination Date."

3.**<u>Employment Period Duties.</u>** During the Employment Period following the Effective Date, the Employee shall be employed by and serve as President of the Company on a full-time basis reporting directly to Chief Executive Officer or any other individual designated by Chief Executive Officer to supervise Employee. The Employee shall perform such duties as are normally associated with the position and such duties as are assigned to Employee from time to time. The Company reserves the right from time to time to change the nature and scope of Employee's duties. Employee hereby agrees and understands that the primary place of work is the Employee's home office in Milton, Georgia, and that Employee may also be required to travel, including travel outside of the United States of America, in furtherance of the duties of the position.

4.**<u>Exclusive Service.</u>** Employee hereby agrees to devote all of his reasonable efforts and business time, attention, and energies to the performance of his duties under this Agreement and to the Company; provided that Employee may serve on the board of directors of purely philanthropic or civic organizations or on the board of directors of one other company that is not competitive with the business of the Company ("Corporate Boards"), in each case only to the extent that such service or participation does not interfere with Employee's employment with the

------

Company or duties under this Agreement. Employee may serve on the board of directors of additional companies that are not competitive with the business of the Company to the extent that such service or participation does not interfere with Employee's employment with the Company or duties under this Agreement and Employee has advised the Company prior to commencing, and the Company has consented (which consent shall not be unreasonably withheld) to such additional Corporate Board service.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.**<u>Restrictive Covenants.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1Employee understands that the Company has spent considerable time, effort and expense developing proprietary information and has taken reasonable measures to protect its secrecy. Therefore, as a condition of employment with the Company, Employee shall execute the Non-Competition, Non-Solicitation and Non-Disclosure, which is attached to the Original Agreement as Exhibit A and incorporated by reference herein (the "NDA" or "Exhibit A"). The NDA is intended to survive and does survive the termination or expiration of this Agreement. The obligations, duties and liabilities of the Employee pursuant to Exhibit A are continuing, absolute and unconditional, and shall remain in full force and effect, despite any termination of this Agreement for any reason whatsoever, with or without Cause.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2Employee has carefully read and considers this Section 5 and the NDA to be fair, reasonable and reasonably required for the protection of the interests of the Company. These provisions may be waived only by a written amendment signed by the parties. In the event Employee breaches any of the covenants in the NDA, any entitlement Employee may have to severance payments pursuant to Section 7 shall be forfeited.

6.**<u>Compensation and Benefits.</u>** As compensation for the services to be performed by the Employee under this Agreement, the Company agrees to pay the Employee, and the Employee agrees to accept the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1**<u>Salary.</u>** The Company shall pay to the Employee an annual base salary of Four Hundred and Ten Thousand US Dollars ($410,000.00) (the "Base Salary") commencing on the Effective Date of this Agreement, which shall be payable in equal installments, not less frequently than bi-weekly, in accordance with the Company's payroll practices; shall be subject to customary and required deductions and withholdings.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2**<u>Discretionary Bonus.</u>** Employee will be eligible to participate in Company's annual bonus plan, subject to its terms and conditions, with the potential to earn a short-term cash bonus under the Company's annual management incentive plan or other similar bonus plan, equivalent to a target percentage of eighty-five percent (85%) of Employee's Base Salary ("Bonus"), based upon achievement of corporate and individual goals. The Company shall pay the Bonus for a calendar year, if at all, on or after January 1st, but by no later than March 15th, of the following calendar year, and Employee must be employed by the Company on the payment date in order to have earned the Bonus. No annual Bonus is guaranteed, and its payment rests in the sole discretion of the Company. The Company may, in its sole discretion, also pay Employee additional bonuses as a result of the achievement of key deliverables.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3**<u>Reserved.</u>**

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4**<u>Incentive Equity Grants.</u>** Employee shall be eligible to receive discretionary equity grants ("Equity Grants") under the Company's Omnibus Long-Term Incentive Plan, as may be amended from time to time ("Omnibus Plan"), based upon achievement of corporate and individual goals. Such Equity Grants are subject to all of the terms and conditions of the Omnibus Plan and any applicable award documents. The vesting schedule, exercise timing and price per unit (as defined in the applicable award agreement) will be determined in accordance with the Omnibus Plan and any applicable award documents. Employee should consult with a tax advisor concerning the tax risks associated with accepting the Equity Grants. The Employee's target annual Equity Grant as of the Effective Date is One Million Three Hundred Thousand US Dollars ($1,300.000).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5**<u>Benefits.</u>** The Employee shall be entitled to participate in the Company's benefit plans, including but not limited to, medical, dental, vision, life and disability insurance plans, subject to the eligibility and contribution requirements, enrollment criteria and the other terms and conditions of such plans. The Company reserves the right to modify, amend and eliminate any such plans, in its sole and absolute discretion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6**<u>Paid Time Off.</u>** Employee shall be entitled to paid vacation and holidays pursuant to the terms of the Company's vacation policy as may exist and be amended from time to time in the sole and absolute discretion of the Company, and in accordance with any applicable laws. Employee shall also be eligible for paid sick days, pursuant to the Company's applicable policy as may exist and be amended from time to time in the sole and absolute discretion of the Company, and in accordance with any applicable laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.7**<u>Expense Reimbursement.</u>** The Company shall reimburse the Employee for any reasonable out-of-pocket business expenses, including for travel, marketing, entertaining or other similar business expenses, incurred by the Employee during the Employment Period in the discharge of the position duties under this Agreement ("Expense"); provided that for each Expense, such Expense was incurred and the related reimbursement request was made, in compliance with the Company's expense reimbursement policy in effect and supported by relevant documentation.

7.**<u>Termination.</u>** Notwithstanding any other provision of this Agreement, the employment relationship between the Company and Employee shall be an at-will employment relationship. Either party may terminate Employee's employment under this Agreement at any time with or without Cause (as defined in Section 7.2). Upon termination of employment pursuant to this Section 7, the Employee shall receive payment of any accrued but unpaid Base Salary through the Termination Date, reimbursement for any unpaid and approved expenses incurred through the Termination Date, and any accrued but unused vacation. On or prior to the Termination Date, Employee shall return to the Company any and all Proprietary Information (as defined in Exhibit A) in the Employee's possession, together with any and all other property of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1**<u>Termination Upon Death or Disability.</u>** In the event of Employee's death or the termination of the Employee by the Company because of his incapacity due to Disability (as defined herein) during the Employment Period, reimbursement for any unpaid and approved expenses incurred through the Termination Date, and any accrued but unused vacation. In the event of Employee's death, those payments will be made to the estate or legal representative of Employee and any death benefits payable and due to the death of Employee under Company

------

benefit plans or programs will also be paid. For the purpose of this Section 7.1, Disability means a mental or physical condition which, in the opinion of the Company as supported by competent medical evidence and after consideration and compliance with its obligations under the Americans with Disabilities Act, and all applicable state and local laws, renders Employee

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION PURSUANT TO**

**RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, David Hart, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of The Cannabist Company Holdings Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: August 7, 2025 | By: | /s/ David Hart |
|  |  | **Name: David Hart** |
|  |  | **Chief Executive Officer** |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION PURSUANT TO**

**RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Derek Watson, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of The Cannabist Company Holdings Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: August 7, 2025 | By: | /s/ Derek Watson |
|  |  | **Derek Watson** |
|  |  | **Chief Financial Officer** |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of The Cannabist Company Holdings Inc. (the "Company") on Form 10-Q for the period ending June 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: August 7, 2025 | By: | /s/ David Hart |
|  |  | **David Hart** |
|  |  | **Chief Executive Officer** |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of The Cannabist Company Holdings Inc. (the "Company") on Form 10-Q for the period ending June 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: August 7, 2025 | By: | /s/ Derek Watson |
|  |  | **Derek Watson** |
|  |  | **Chief Financial Officer** |

---

<br>